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ABSTRACT	Despite	 the	 recent	 success	 of	 immune-checkpoint	 blockade	 therapy	 for	 late-stage	non-small	cell	 lung	cancer	(NSCLC),	 lung	cancer	is	still	 the	leading	cause	of	cancer	deaths	worldwide.	One	of	the	most	important	characteristics	of	lung	cancer	in	therapeutic	decision-making	are	the	targetable	molecules,	including	EGFR,	ALK,	BRAF,	and	MEK.	The	excitement	of	 immune-checkpoint	 blockade	 therapy	 has	 triggered	 concerted	 efforts	 that	 focus	 on	exploring	 combinations	 of	 immune	 checkpoint	 therapy	with	 other	 approved	 therapeutic	regimens	aiming	at	further	augmenting	positive	outcomes	and	survival.	However,	the	lack	of	understanding	of	underlying	mechanisms	and	evidence-based	clinical	testing	has	hindered	the	progress	to	a	cure.	Hence,	the	goal	of	the	study	presented	here	is	to	elucidate	the	cross-talk	between	targeted	agents	and	cytokine	response	pathways	in	cancer	cells.		The	goal	of	the	first	part	of	this	study	was	to	investigate	the	molecular	mechanisms	of	cancer	cells	 in	response	to	MEK	inhibitors	(MEKi),	through	which	lung	cancer	cells	are	rendered	sensitive	to	TNFα	and	IFNγ.	We	found	that	BRAF	inhibitor	and	MEKi	treatment	of	melanoma	patients	led	to	the	activation	of	tumor	NF-κB	activity.	In	vitro	studies	revealed	that	MEKi	potentiate	the	response	to	TNFα,	a	potent	activator	of	NF-κB.	In	both	melanoma	and	lung	cancer	cells,	MEKi	induced	a	strong	increase	in	the	cell	surface	expression	of	TNF
 	 receptor	 1	 (TNFR1),	 subsequently	 enhancing	 NF-κB	 activation	 and	 augmenting	 the	expression	of	genes	regulated	by	TNFα	and	IFNγ.	Screening	of	289	targeted	agents	for	the	ability	to	increase	TNFα	+	IFNγ	target	gene	expression	demonstrated	that	this	was	a	general	
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activity	of	inhibitors	of	MEK	and	ERK	kinases.	Treatment	with	MEKi	led	to	the	acquisition	of	a	 novel	 vulnerability	 to	 TNF 	 +	 IFNγ-induced	 apoptosis	 in	 lung	 cancer	 cells	 that	 were	refractory	to	MEKi	killing	as	well	as	the	augmentation	of	cell	cycle	arrest.	Lung	cancer	cell	knock-out	 of	 TNFR1	 impaired	 the	 anti-tumor	 efficacy	 of	 MEKi,	 whereas	 TNFα	 +	 IFNγ	administration	 in	 MEKi-treated	 mice	 enhanced	 the	 anti-tumor	 response.	 Finally,	immunotherapeutics	 known	 to	 induce	 the	 expression	of	 these	 cytokines	 synergized	with	MEKi	 in	eradicating	 tumors.	These	 findings	define	a	novel	 cytokine	response	modulatory	function	of	MEKi	that	can	be	therapeutically	exploited.		The	 second	 part	 of	 this	 study	 explored	 the	 above-described	 concept	 in	 a	 more	translationally	 relevant	 setting.	 In	 immune	 therapies,	 TNF 	 and	 IFNγ	 are	 primarily	produced	 by	 tumor-infiltration	 lymphocytes	 (TILs)	 that	 are	 adoptively	 transferred	 or	reactivated	 by	 immune-checkpoint	 blockade.	 Whereas	 activated	 T	 cells	 recognize	 and	eliminate	 specific	antigen-expressing	cancer	cells,	 the	cytokines	secreted	by	 those	T	cells	impact	broader	 targets,	 including	 those	 that	are	able	 to	escape	 from	direct	T	cell	antigen	recognition.	 This	 non-specific	 anti-tumor	 effect	 is	 important	 for	 long-term	 therapeutic	response	 but	 is	 currently	 overlooked	 and	 less	 exploited.	 To	 understand	 the	 relative	contribution	of	the	cytokine	mediated	killing,	an	in	vitro	co-culture	system	that	measures	target	 cell	 survival	 via	 a	 firefly	 bioluminescence	 assay	was	 used.	We	 demonstrated	 that	cytokines	secreted	by	activated	T	cells	contribute	significantly	to	an	anti-tumor	effect	and	can	 be	 further	 enhanced	 by	 MEKi,	 depletion	 of	 TNFα,	 and	 IFNγ	 signaling,	 all	 of	 which	dampened	the	overall	anti-tumor	effect	and	resulted	in	a	loss	of	synergy	with	MEKi.	These	findings	provided	further	evidence	for	the	development	of	a	pre-clinical	model	and	clinical	approach	to	combine	immune	therapies	with	MEKi	for	lung	cancer	treatment.		
viii	
Overall,	we	show	that	lung	cancer	cells	are	rendered	sensitive	to	MEKi	by	TNF	and	IFNγ,	 providing	 a	 strong	 mechanistic	 rationale	 for	 combining	 MEKi	 with	immunotherapeutics	that	enhance	the	expression	of	these	cytokines.
1 
CHAPTER	1	BACKGROUND	
Non-small	cell	lung	cancer	(NSCLC)	Lung	 cancer	 is	 the	 leading	 cause	 of	 cancer	 death	 worldwide.	 Many	 lung	 cancer	patients	are	diagnosed	with	advanced	disease.	NSCLC	is	defined	as	any	type	of	epithelial	lung	cancer	other	than	small	cell	lung	carcinoma	(SCLC);	and	accounts	for	80–85%	of	lung	cancers.	Adenocarcinoma	 and	 squamous	 cell	 carcinomas	 are	 two	 major	 subtypes	 of	 NSCLC.	 The	survival	rates	decrease	significantly	due	to	the	advancement	of	 the	disease.	The	five-year	survival	rate	for	localized	disease	is	60%,	and	33%,	6%	for	regional	and	distant	metastasis,	respectively,	based	on	people	diagnosed	with	NSCLC	between	2008	and	2014	1.		Lung	cancer	 is	amongst	 the	cancer	 types	 that	harbor	high	genetic	mutations,	with	somatic	mutations	 in	many	 different	 genes	 having	 been	 found	 in	 lung	 cancer	 cells2.	 For	example,	 the	 oncogenic	KRAS	mutation	occurs	 in	 approximately	 32%	of	 adenocarcinoma	patients,	and	the	EGFR	mutation	is	found	in	about	10%	of	Western	adenocarcinoma	patients;	less	frequent	mutations	and	genetic	alternations	include	BRAF	(2%),	ALK	(4%),	and	PI3KCA	(2%).3.	 Although	many	 of	 the	 targetable	 mutations	 are	 providing	 vast	 opportunities	 for	selectively	 targeting	 cancer	 cells,	 the	 intrinsic	 and	 adaptive	 resistance	 due	 to	 genetic	heterogeneity	of	tumor	tissue	also	introduces	significant	challenges	to	targeted	therapies.	The	standard	treatment	options	for	early-stage	(<III)	NSCLC	patients	are	surgery	and	radiotherapy.	Adjuvant	chemotherapy	after	surgery	may	also	lower	the	risk	that	the	cancer	will	 return.	 Forty	 percent	 of	 newly	 diagnosed	 NSCLC	 are	 stage	 IV	 disease.	 Standard	treatment	 options	 for	 newly	 diagnosed	 stage	 IV,	 relapsed,	 and	 recurrent	 NSCLC	 include	
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cytotoxic	chemotherapy	and	targeted	agents	(monoclonal	antibodies	that	target	EGFR,	and	tyrosine	kinase	inhibitors	(TKIs)	that	target	oncogenes	such	as	mutated	EGFR,	BRAFV600E,	and	ALK	rearrangements).	In	2015,	humanized	monoclonal	antibody	pembrolizumab	was	approved	 for	 the	 treatment	 of	 advanced	 NSCLC,	 this	 antibody	 inhibits	 the	 interaction	between	the	immune	inhibitory	receptor	programmed	cell	death	protein	1	(PD-1)	and	its	ligands	 PD-L1	 and	 PD-L2,	 prevents	 the	 effector	 T	 cell	 exhaustion	 induced	 by	 inhibitory	signals.		Patients	 received	 surgical	 removal	 of	 the	 tumor	 often	 develop	 regional	 or	 distant	metastases,	and	radiation	therapy	may	improve	5-	or	2-year	overall	survival	(OS)	for	a	small	number	of	patients.	For	the	patients	with	late-stage	or	relapsed	NSCLC,	targeted	therapies	may	 bring	 clinical	 benefit	 to	 a	 subset	 of	 patients	who	 possess	 certain	 genetic	 attributes;	targeted	 therapies	 also	 have	 favorable	 toxicity	 profiles	 compared	 with	 conventional	cytotoxic	chemotherapy.	Using	EGFR	TKIs	to	treat	patients	that	harboring	a	targetable	EGFR	driver	mutation	is	the	most	significant	paradigm	change	for	lung	cancer	treatment.	The	top	two	EGFR	mutations	are	exon	19	deletion	and	L858R	missense	substitutions,	which	occur	in	60%	and	35%	patients,	 respectively.	Those	activating	mutations	are	considered	as	prime	therapeutic	 target	 4,	 	which	 can	be	 inhibited	by	 small	molecule	TKI	 such	as	gefitinib	and	erlotinib	and	receptor	monoclonal	antibodies	such	as	cetuximab.	In	the	landmark	trial	Iressa	Pan-Asia	Study	(IPASS),	gefitinib	has	achieved	12-month	progression-free	survival	(PFS)	in	24.9%	 untreated	 stage	 IIIB	 or	 IV	 adenocarcinoma	 patients,	 compared	 to	 6.7%	 in	chemotherapy	group	5.	Another	 targetable	genetic	aberration	 is	 the	anaplastic	 lymphoma	kinase	 (ALK)	 fusion	 oncogene,	 it	 occurs	 in	 3-7%	 of	 NSCLC	 6.	 ALK	 rearrangements	 are	mutually	exclusive	from	EGFR	or	KRAS	mutations	in	cancers,	it	promotes	cancer	cell	growth	
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and	 proliferation,	 tumors	 harboring	 ALK	 fusion	 oncogene	 exhibit	 the	 prototype	 for	‘oncogene	 addiction’	 where	 a	 single	 oncogene	 drives	 the	 development	 of	 malignancy	 7,	Crizotinib	 is	an	oral	 small	molecule	 inhibitor	 	 targeting	 the	ALK,	MET	and	ROS1	 tyrosine	kinases	 8.	 It	 was	 approved	 in	 2011	 for	 the	 treatment	 of	 advanced	 NSCLC	 that	 express	abnormal	ALK,	based	on	the	57%	overall	response	rate	(ORR)	and	a	PFS	of	9.7	months	in	clinical	 data	 9,10.	 The	 BRAFV600E	 mutation	 occurs	 in	 1–2%	 of	 lung	 adenocarcinoma.	 A	combination	of	 the	BRAF	 inhibitor	dabrafenib	and	 the	MEK1/2	 inhibitor	 trametinib	have	received	approval	for	treatment	of	metastatic	NSCLC	patients	who	harboring	BRAFV600E	mutations—this	combination	achieved	a	63%	overall	response,	among	those	responders,	64%	reached	a	durations	≥6	months	11.	The	PD-1	blockade	antibody	pembrolizumab	brings	long-term	clinical	benefit	 to	advanced	NSCLC	patients	who	have	tested	positive	 for	PD-L1;	 the	median	 OS	 in	 responders	 was	 16.7	 to	 20	months	 depending	 on	 PD-L1	 expression	 level.	Despite	having	a	lower	response	rate	(~20%),	pembrolizumab	received	FDA	approval	for	first-line	treatment	of	NSCLC	patients	whose	PD-L1	expression	level	is	>	1%	12,13.		 Despite	the	significant	achievements	of	modern	drug	discovery,	further	development	of	novel	and	more	efficient	treatments	for	NSCLC	are	still	urgently	required,	especially	for	those	 without	 RTK	 aberrations.	 Therapies	 currently	 in	 the	 clinical	 and	 pre-clinical	development	pipeline	 include	novel	small	molecular	agents	and	combination	approaches.	AMG	510	is	the	first	KRASG12C-specific	inhibitor	to	reach	the	clinical	stage	after	decades	of	KRAS	research.	In	2019,	the	Phase	I	clinical	trial	data	revealed	a	50%	(5	out	of	10)	partial	response	 (PR),	 4	 other	 stable	 disease	 (SD)	 in	NSCLC	patients,	 90	percent	 (9/10)	 disease	control	 rate	 (DCR)	 in	 total	 14,15.	 AMG	510	has	high	potential	 as	 both	 a	monotherapy	 and	possibly	 in	 combination	 with	 other	 targeted	 and	 immune	 therapies.	 Combination	 of	
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approved	 TKIs	 such	 as	 ALK	 inhibitors	 and	 EGFR	 inhibitors	 with	 immune	 checkpoint	blockade	 are	 currently	 under	 clinical	 assessments	 in	 NSCLC16.	 Other	 than	 TKIs,	 histone	deacetylase	 (HDAC)	 inhibitors	 have	 been	 found	 to	 have	 a	 potential	 therapeutic	 role	 in	diverse	malignancies,	including	NSCLC	through	modification	of	transcription17-19.	Preclinical	studies	from	our	laboratory	using	lung	cancer	murine	models	also	demonstrated	that	HDAC	inhibitors	 improve	 T	 cell	 trafficking	 to	 tumors	 and	 enhancing	 T	 cell	 function,	 therefore	enhance	the	response	to	PD-1	blockade	20;	this	work	led	to	a	phase	1/1b	study	conducted	at	the	 Moffitt	 Cancer	 Center	 which	 combined	 pembrolizumab	 and	 the	 HDAC	 inhibitor	vorinostat	 in	 the	 treatment	of	33	patients	with	advanced	or	metastatic	NSCLC	 21.	Clinical	trials	combining	radiotherapy	and	immunotherapy	are	also	attracting	significant	attention22.	The	 above	 representative	 examples	 are	 only	 a	 small	 fraction	 of	 the	 novel	 therapies	undergoing	 development	 and	 evaluation,	 in	 combination	 with	 other	 types	 of	 immune	therapy,	 such	as	adoptive	cell	 therapies	and	vaccines	 that	are	also	highly	active	 research	domains	for	NSCLC.		
Melanoma		 Skin	cancer	is	the	most	common	malignancy	diagnosed	in	the	United	States.	Invasive	melanoma	represents	approximately	1%	of	skin	cancers	but	results	in	the	most	deaths.	In	2019,	the	estimated	number	of	melanoma	diagnoses	in	the	United	States	is	96,480,	with	a	death	incidence	of	7,230.		Melanoma	arises	from	transformed	melanocytes.	Patients	diagnosed	with	early-stage	melanomas	generally	have	a	high	5-year	survival	rate	(>90%);	surgical	excision	remains	the	primary	modality	for	treating	early-stage	melanoma	(stage	0,	I,	II,	and	resectable	Stage	III	
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melanoma).	The	primary	cause	of	malignancy	is	sun	exposure.	DNA	damage,	and	defective	repair	due	to	ultraviolet	radiation	that	leads	to	mutations	that	contribute	to	tumorigenesis	years	before	the	cancer	becomes	symptomatic23.	Understanding	the	genomic	landscape	of	melanoma	is	highly	important	for	therapeutic	development	and	clinical	decision-making	for	the	 treatment	 of	 late-stage	 and	 recurrent	 melanoma.	 The	 Cancer	 Genome	 Atlas	 (TCGA)	project	led	by	the	NCI	has	identified	4	major	genomic	subtypes	of	melanoma,	namely	BRAF	mutant,	RAS	mutant,	NF1	mutant,	and	triple	wild	type24.	To	date,	targeted	therapies	have	demonstrated	 efficacy	 and	 received	 FDA	 approval	 for	 the	 BRAF-mutant	 subtype	 of	melanoma	 only;	 notably,	 the	 BRAF	 mutation	 is	 involved	 in	 52%	 of	 melanomas.	 A	combination	 of	 BRAF	 +	 MEK	 inhibitors	 (i.e.	 vemurafenib	 +	 cobimetinib,	 dabrafenib	 +	trametinib,	encorafenib	+	binimetinib)	has	so	far	been	considered	the	most	effective	targeted	therapy	 for	melanoma.	Forty	one	percent	progression-free	survival	has	been	observed	 in	dabrafenib	 +	 trametinib	 group,	 compared	 to	 9%	 in	 dabrafenib	 alone,	 and	 the	 median	progression-free	survival	in	combination	groups	was	9.4	months	versus	5.8	months	in	mono	treatment	group25.		Targeted	 therapies	 that	 repress	 oncogenic	 signals	 in	 melanoma	 have	 achieved	significant	 success	 compared	 to	 cytotoxic	 chemotherapy	 approaches,	 and	 they	 have	 also	conceptually	demonstrated	a	good	design	rationale	for	anti-cancer	therapies.	Nevertheless,	targeted	therapies	often	place	a	selection	pressure	on	the	malignant	cells	and	always	induces	drug	 resistance;	 hence,	 the	 clinical	 benefit	 of	 those	 targeting	 agents	 mostly	 involves	prolonging	survival	rather	than	durable	tumor	control	or	cure.	Fortunately,	the	advances	in	understanding	immuno-oncology	have	brought	revolutionary	improvement	to	anti-cancer	treatment	in	the	past	decade.	Melanoma	is	the	type	of	cancer	that	has	demonstrated	the	most	
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impactful	 and	 successful	 clinical	 results	 from	 immunotherapies,	 particularly	 immune	checkpoint	inhibition,	which	revitalizes	tumor-infiltrating	lymphocytes	(TILs).	It	is	believed	that	the	high	somatic	mutational	load	caused	by	UV	damage	distinguishes	melanoma	from	non-cutaneous	tumors.	Such	mutations	alter	protein	epitopes	that	are	then	capable	of	being	processed	 and	 presented	 by	 antigen-presenting	 cells	 (APCs)	 as	 tumor	 antigens;	 immune	cells	including	cytotoxic	T-lymphocytes	(CTLs)	will	attack	malignant	cells	that	express	such	antigens.	 Indeed,	 studies	 have	 shown	 that	 high	 levels	 of	 CD8+	TILs	 promoted	 prolonged	patient	survival	compared	to	patients	lacking	such	an	infiltrate26,27.	The	mechanism	of	immune	checkpoint	inhibitors	involves	blocking	the	binding	of	the	ligand	 and	 receptor	 of	 the	 coinhibitory	 signal	 during	 an	 immune	 response.	 Ipilimumab,	pembrolizumab,	 and	 nivolumab	 are	 approved	 immune	 checkpoint	 inhibitors	 for	 the	treatment	 of	 metastatic	 melanoma.	 Ipilimumab	 is	 a	 human	 IgG1	 monoclonal	 antibody	against	CTLA4	that	outcompetes	the	costimulatory	receptor	CD28	for	its	ligands	CD80	and	CD86.	According	 to	 a	pooled	analysis	of	12	 clinical	 trials,	 approximately	22%	of	patients	treated	with	ipilimumab	have	reached	the	10-year	overall	survival,	suggesting	a	sustained	response	 rate28.	 Pembrolizumab	 and	 nivolumab	 are	 human	 IgG4	monoclonal	 antibodies	targeting	PD-1,	another	T	cell	receptor	co-inhibitory	molecule.	The	longest	follow-up	study	for	advance	melanoma	patients	receiving	pembrolizumab	in	KEYNOTE-001	revealed	a	34%	overall	5-year	survival	rate,	of	which	73%	responses	are	still	ongoing.	41%	5-year	survival	rate	was	also	achieved	with	 treatment-naïve	patients	 29.	Besides	 that,	 numerous	ongoing	clinical	 and	 preclinical	 studies	 are	 being	 rapidly	 developed	 aiming	 at	 discovering	 novel	agents,	 achieving	 higher	 response	 rate,	 optimizing	 dosing	 sequence,	 and	 defining	biomarkers	for	personalized	treatment	as	well	as	prognostic	prediction30.	
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Targeting	RAS	oncogenic	signaling	in	NSCLC	and	Melanoma	
Targetable	RAS	oncogenic	signaling	The	product	of	 the	Kras	gene	 is	a	12KDa	GTPase.	KRAS	acts	as	a	molecular	on/off	switch;	it	binds	to	guanosine	triphosphate	(GTP)	in	its	active	state,	and	cleaves	the	terminal	phosphate	 of	 the	nucleotide	 to	 convert	GTP	 to	 guanosine	diphosphate	 (GDP)	 through	 its	intrinsic	enzymatic	activity.	Upon	conversion	of	GTP	to	GDP,	KRAS	is	deactivated.	Normally,	activation	of	KRAS	is	triggered	by	hormone	binding	to	an	appropriate	cell	surface	receptor,	such	 as	 the	 binding	 of	 growth	 factor	 to	 EGFR.	 The	 adaptor	 protein	 GRB2	 binds	 to	 the	cytoplasmic	domain	of	ligand-activated	receptors	and	other	downstream	effector	proteins	through	its	Src-homology	(SH)	domains	SH2	and	SH3,	respectively.	The	SH3	domain	binds	to	proline-rich	motifs	on	the	carboxy	terminus	of	Son	of	Sevenless	(SOS)	.	Upon	growth	factor	receptor	 activation,	 the	 GRB2/SOS	 complex	 moves	 from	 the	 cytoplasm	 to	 the	 activated	tyrosine	 phosphorylated	 receptors;	 this	 translocation	 is	 thought	 to	 bring	 SOS	 into	 close	proximity	with	RAS	to	catalyze	nucleotide	exchange,	leading	to	the	activation	of	RAS31,32	(Fig.	
1.1).		 Upon	activation,	RAS	transduces	signals	to	its	downstream	pathways.	The	most	well-defined	downstream	pathways	 involved	 in	 cancer	development	 are	 those	 involving	RAF-MEK-ERK,	PI3K-AKT-mTOR,	and	RalGDS-RalA/B,		all	of	which	regulate	a	wide	spectrum	of	survival	promoting	functions,	including	cell	proliferation	and	differentiation,	metastasis	and		cellular	 metabolism.	 In	 normal	 tissues,	 those	 signals	 are	 strictly	 regulated,	 whereas	oncogenic	 RAS	 usually	 triggers	 aberrant	 downstream	 signals	 that	 lead	 to	 malignant	transformation33.	The	most	common	mutations	of	the	Kras	gene	often	occur	through	a	G➔ 
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A	transition	in	codons	12	or	13,	resulting	in	G12D	or	G13D	mutations,	 followed	by	G➔ T	transition	that	produce	G12V34,35.	KRASG12C	mutations	predominate	in	NSCLC,	comprising	11–16%	of	lung	adenocarcinomas	36,37.	The	mutant	forms	disable	the	conversion	of	GTP	to	GDP,	 resulting	 in	 constitutive	 activation	 of	 downstream	 signals,	which	 ultimately	 lead	 to	tumorigenesis.	 Unlike	 NSCLC,	 mutations	 in	 KRAS	 is	 rare	 in	 melanoma	 patients	 (1-2%),	however	mutations	in	NRAS	occur	in	15%–20%	of	all	human	melanomas.	The	most	common	NRAS	mutations	occur	at	position	61	(Q61).	Unfortunately,	no	therapeutic	agents	have	been	approved	specifically	for	NRAS-mutant	melanoma	38.		
	
Figure	1.1	RAS-RAF-MEK-ERK	signaling.				
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Diagram	shows	activation	of	RAS-RAF-MEK-ERK	signaling	upon	tyrosine	kinase	receptors	binding	to	their	ligands.	 GRB2	 binds	 to	 ligand-activated	 growth	 factor	 receptors	 and	 downstream	 effector	 proteins	through	 adaptor	 proteins	 SHC-GRB2-SOS.	 The	 phosphorylation	 and	 activation	 of	 RAF-MEK-ERK	 is	triggered	 upon	 RAF	 interacting	 with	 RAS-GTPase	 at	 the	 plasma	 membrane.	 Activated	 ERK	 then	translocates	into	the	nucleus	to	regulate	the	expression	of	genes	that	are	associated	with	cell	proliferation	and	growth.			Direct	targeting	of	RAS	is	difficult	because	the	RAS	proteins	do	not	appear	to	present	suitable	pockets	 to	which	drugs	could	bind.	RAS	proteins	also	bind	particularly	 tightly	 to	nucleotides,	 making	 the	 prospect	 of	 identifying	 competitive	 nucleotide	 analogs	 seem	virtually	 impossible39.	 Recently,	 KRASG12C	 was	 identified	 to	 be	 druggable.	 A	 newly	discovered	 pocket	 named	 SII-P	 in	 the	 SW2	 region	 of	 GDP-bound	 inactive	 RAS	 can	 be	covalently	bounded	by	selective	compounds,	disrupting	SW1	and	SW2,	thereby	preventing	SOS-mediated	 GDP/GTP	 switch	 40.	 Indeed,	 selective	 KRASG12C	 inhibitors	 have	 showed	therapeutic	potency	in	pre-clinical	models	and	early	clinical	trials	(also	discussed	in	page	3)15,41,42.	The	 predominant	 drug	 development	work	 targeting	KRAS	 signaling	 networks	 has	focused	on	the	more	well-studied	and	druggable	downstream	signaling	molecules	(Fig.	1.1).	RAF	kinases	are	a	family	of	three	serine/threonine-specific	protein	kinases	(A-RAF,	B-RAF,	and	c-Raf).	The	activation	of	Raf	is	triggered	upon	interacting	with	RAS-GTPase	at	the	plasma	membrane.	This	leads	to	downstream	activation	of	MEK	(MAP/ERK	Kinase),	which	regulates	the	activation	of	the	Jun/AP-1	transcription	factors	that	are	primarily	responsible	for	cell	proliferation	and	survival43.	BRAF	mutations	are	 frequent	 in	melanoma	(~50%),	but	also	occur	 in	 lung	 (~2%),	 and	 colorectal	 cancers	 (~10%).	 A	 valine	 to	 glutamic	 acid	 (V600E)	substitution	 accounts	 for	 80%	 of	 BRAF	mutations	 in	 melanoma44,45.	 Other	 less	 frequent	BRAF	mutations	have	also	been	identified		from	melanoma	patient	biopsies	such	as	V600K	
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(16%)	and		V600D/V600R	(3%)	46.	The	mutations	of	BRAF	result	in	constitutive	activation	of	oncogenic	MAP	Kinase	signaling.		MEK	plays	central	roles	in	the	MAPK	signaling	transduction.	MEK1/2	(MAPKK)	are	tyrosine	(Tyr)	and	serine	(Ser)/	threonine	(Thr)	dual-specificity	kinases,	and	are	primarily	phosphorylated	and	activated	by	RAF;	activated	MEK1/2	then	phosphorylates	and	activates	the	 ERK1	 and	 ERK2	MAPKs.	 Notably,	 RAF	 is	 considered	 to	 be	 only	 a	 subset	 of	MEK1/2	activators,	 whereas	 MEK1	 and	 MEK2	 are	 the	 exclusively	 specific	 activators	 of	 ERK1/2;	therefore,	MEK1/2	serve	a	unique	role	as	crucial	 “gatekeepers”	 in	 the	MAPK	cascade47,48.	Inactivated	 ERK1/2	 are	 located	 in	 the	 cytoplasm;	 their	 activation	 involves	 the	phosphorylation	of	Thr202	 and	Tyr204	of	 ERK1	and	Thr173	 and	Tyr185	of	 ERK2.	Upon	activation,	 they	 are	 translocated	 to	 the	 nucleus	 and	 activate	 a	 variety	 of	 transcriptional	factors	such	as	CREB,	NF-κB,	c-Myc,	and	 Jun/AP-1	(Fig.	1.1).	The	 feedback	regulations	of	ERK	can	be	mediated	by	its	substrates,	different	substrates	lead	to	either	positive	or	negative	feedback	 signals	 49.	 Negative	 feedback	 is	 often	 considered	 to	 be	 one	 of	 the	 major	 drug	resistance	 mechanisms;	 therapeutic	 strategies	 that	 overcome	 this	 resistance	 include	combination	 therapies	 that	 target	 two	 or	more	 kinases	 (e.g.	 BRAF/MEK).	 Recent	 studies	have	also	identified	SHP2	as	a	crucial	mediator	of	the	negative	feedback	loop	and	inhibition	of	SHP2	in	addition	to	MAPK	signaling	blockade,	which	brings	improved	therapeutic	effects	to	BRAF	mutant	melanoma50.		
Drug	resistance	mechanisms	of	targeting	RAS	oncogenic	signaling	In	addition	to	reactivation	of	the	RAS-RAF-MEK-ERK	axis	through	negative	feedback,	many	other	mechanisms	have	also	been	investigated,	and	therapeutic	approaches	that	aim	at	overcoming	drug	resistance	have	been	evaluated.	Secondary	mutations	in	BRAF	(L514V)	
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and	 an	 acquired	 NRASQ61K	mutation	were	 reported	 to	 be	 responsible	 for	 resistance	 in	paitents51,52.	 The	 activation	 of	 the	 parallel	 signaling	 pathway	 PI3K-AKT-mTOR	 is	 also	considered	 to	 be	 an	 important	 acquired	 drug	 resistance	 mechanism.	 In	 melanoma,	vemurafenib	treatment	can	increase	the	level	of	growth	factor	(HGF)	produced	by	fibroblasts,	therefore	activates	PI3K	signaling	pathways,	and	reactivates	MAPK	pathway	as	well.	Dual	inhibition	of	BRAF/MEK	and	PI3K	/AKT	has	its	own	mechanistic	rationale	and	has	shown	sensitivity	in	solid	tumors53,54.	However,	this	strategy	was	hindered	by	greater	toxicity.	In	a	Phase	I	study,	drug-related	grade	>III	adverse	events	were	found	in	53.9%	patients	received	dual	 inhibitors	 compared	 to	 18.1%	 in	 mono	 therapy	 group	 55.	 Hypoxia	 in	 the	 tumor	microenvironment	due	to	anaerobic	glycolysis	(the	so-called	Warburg	effect)	is	also	found	to	 contribute	 to	 drug	 resistance	 via	 multiple	 mechanisms.	 Cancer-associated	 fibroblasts	(CAFs)	 secrete	 a	 β-catenin	 inhibitor,	 sFRP2,	which	 increases	 oxidative	 stress	 to	 augment	vemurafenib	resistance56.	Hypoxia	was	also	shown	to	inhibit	tumor-associated	neutrophil	(TAN)	 apoptosis.	 As	 a	 result,	 TANs	 secrete	 CCL2	 and	 CCL17	 to	 recruit	 inflammatory	macrophages	 and	 Treg	 cells,	 which	 eventually	 allow	 tumor	 cells	 to	 escape	 immune	surveillance57.		
NSCLC	and	melanoma	respond	differently	to	targeting	of	RAS	signaling		It	is	notable	that	therapies	that	target	RAS	oncogenic	signaling	show	varied	response	rates	and	efficacy	across	different	cancers,	potentially	due	to	variable	levels	of	“addiction	to	constitutive	BRAF	signaling”.	This	difference	of	sensitivity	is	not	limited	to	a	single	agent	but	also	 appears	 in	 the	 setting	 of	 combination	 therapies:	 targeting	 RAS	 signaling	 showed	 a	particularly	significant	clinical	efficacy	in	melanoma	compared	to	other	cancers58,59.	In	order	to	achieve	comparable	extent	of	clinical	efficacy	and	response	rate,	it	often	requires	more	
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than	dual	drug	combinations	to	target	the	RAS	signaling	in	other	cancer	types	compared	to	in	BRAFV600E	mutant	melanoma;	however,	it	is	also	evident	that	even	in	BRAFV600-mutant	melanoma,	the	benefit	of	dual	BRAF/MEK	inhibition	is	mostly	limited	to	extension	of	patient	lifespan	 but	 not	 the	 complete	 cure	 of	 disease.	 In	 contrast	 to	 BRAF	 mutant	 melanoma,	targeting	the	RAS	pathway	in	NSCLC	has	been	less	encouraging60,61;	for	example,	the	single-agent	 MEK	 inhibitor	 trametinib	 failed	 to	 improve	 upon	 docetaxel	 in	 terms	 of	 PFS	 and	response	rate	in	previously	treated	KRAS-mutant-positive	NSCLC	patients	61.	The	only	FDA-approved	 approach	 so	 far	 involves	 use	 of	 the	 BRAFV600E	 and	 MEK	 inhibitors	 for	 lung	adenocarcinomas	 patients	with	 BRAFV600E	mutations,	which	 only	 accounts	 for	 1-2%	of	NSCLC.	 New	 strategies,	 therefore,	must	 be	 developed	 for	 the	 treatment	 of	 KRAS	mutant	NSCLC.	
Novel	implications	of	targeted	therapies	In	 recent	 years,	 investigation	 of	 small-molecule	 compounds	 has	 extended	 beyond	pharmacological	mechanisms	of	specific	target-compound	interaction	because	studies	have	uncovered	 the	 far	 more	 complex	 biological	 impacts	 of	 small	 molecules.	 For	 example,	 in	addition	to	their	direct	impact	on	targeting	kinases	in	cancer	cells,	they	can	also	impact	the	tumor	microenvironment.	Studies	by	Brea	et	al.	identified	MAP2K1	and	EGFR	as	important	negative	 regulators	 of	 surface	 HLA-A62;	 furthermore,	 the	 authors	 found	 that	 selective	inhibitors	 such	as	afatinib	and	 trametinib	 that	 target	 the	EGFR	or	MAP	kinase	pathways,	respectively,	 led	 to	 HLA-A	 upregulation	 in	 cell	 lines	 harboring	 EGFR	 or	 BRAFV600E	mutations.	The	upregulated	HLA	expression	also	demonstrated	enhanced	presentation	of	tumor	 antigens62,	 which	 is	 an	 important	 determinant	 of	 efficacy	 for	 certain	immunotherapies63.		
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MAP	kinase	inhibition	was	also	found	to	promote	T	cell	anti-tumor	activity	in	vivo64.	Although	MAP	kinase	signaling	is	essential	in	T	cell	activation	through	recognition	of	antigen	via	antigen-presenting	cells	(APCs)	65,	and	previous	research	indicates	that	pharmacological	inhibition	 of	 MEK	may	 impair	 priming	 and	 proliferation	 of	 naive	 T	 cells	 in	 response	 to	antigen	stimulation66,	an	in	vivo	study	using	a	CT26	colon	carcinoma	model	suggested	that	potent	and	highly	selective	MEK	inhibitors		promote	the	effector	phenotype	and	prevent	the	apoptosis	of	tumor-infiltrating	CD8+	T	cells	after	chronic	exposure	to	antigens.	Overall,	MEK	inhibitors	plus	immune	checkpoint	blockade	impeded	the	growth	of	subcutaneous	tumors	in	mice	64.	Moreover,	analysis	of	melanoma	patient	biopsies	after	BRAF	and	MEK	inhibitor	treatment	indicates	the	increased	presence	of	TILs	and	a	favorable	tumor	microenvironment	that	enhances	the	response	to	immunotherapy64,67-72.	Those	discoveries	provided	a	strong	rationale	 for	 combining	 MAPK	 targeting	 therapy	 with	 immune	 therapy	 and	 therefore,	 a	better	 understanding	 of	 the	 cross-talk	 between	 MAPK	 signaling	 and	 the	 tumor	microenvironment	will	facilitate	translating	those	novel	concepts	to	clinical	practice.			
TNF	receptor	and	NF-κB	signaling	
NF-κB	complex	and	rapid	response	factor	paradigm	NF-κB	(nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells)	is	a	rapidly	inducible	transcription	factor	complex	that	is	widely	expressed	in	almost	all	cell	types.	It	plays	broad	and	significant	roles	in	the	regulation	of	many	physiopathology	processes,	including	innate	and	adaptive	immunological	response,	cell	survival,	and	tumorigenesis.	It	was	discovered	30	years	ago	by	Ranjan	Sen	in	the	laboratory	of	Nobel	laureate	David	Baltimore73.	NF-κB	was	first	found	to	bind	a	specific	conserved	DNA	sequence	(kappa	light	chain	enhancer	sequence)	
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in	the	nuclei	of	activated	B	lymphocytes.	Early	studies	established	NF-κB	as	a	paradigm	of	a	rapid	response	factor	that	the	entire	pathway	is	held	in	latency	but	the	signaling	components	response	immediately	and	in	an	order	way	upon	stimulation,	once	the	signal	transduction	achieves	the	resolution,	the	pathway	then	resets	to	latency.	This	paradigm	is	important	for	keeping	 immune	 system	 homeostasis,	 at	 the	 mean	 time	 enables	 rapid	 innate	 immune	response	to	infection	.	As	time	has	passed,	more	studies	have	revealed	that	NF-κB	is	a	family	of	 related	 protein	 complexes	 that	 work	 as	 hetero	 and	 homodimers;	 this	 signaling	transduction	process	also	involves	diversified	intermediate	factors	and	biochemistry	events,	requires	 tight	 regulation	 of	 the	 enzyme	 activities.	 Protein-protein	 dimerization,	phosphorylation,	and	ubiquitination	are	all	playing	 indispensable	roles.	As	a	result,	many	downstream	 signaling	 pathways	 and	 genes	 that	 are	 targeted	 by	 NF-kB	 are	 not	 fully	understood;	 therefore,	 the	 primary	 focus	 of	 this	 study	 is	 on	well-known	 targets	 such	 as	cytokines	 that	 are	 involved	 in	 immune	 surveillance	 and	 apoptosis	 signaling,	 and	 their	relationship	with	the	RAS-MAPK	signaling	pathway.	The	NF-κB	family	comprises	five	Rel	transcription	factor	family:	NF-κB1	(p105/p50),	NF-κB2	(p100/p52),	Rel	A	(p65),	Rel	B,	and	c-Rel,	all	of	which	share	N-terminal	homology	with	the	v-Rel	oncogene74.	The	Rel	homology	domain	(RHD)	has	three	functions:	sequence-specific	DNA	binding,	dimerization	with	other	 family	members,	 and	binding	of	 inhibitory	protein	 (IκB).	 Three	 family	members—RelA,	RelB,	 and	 c-Rel—are	 synthesized	 as	mature	proteins	with	 transcription	 transactivation	 domains	 (TADs),	whereas	 p50	 and	 p52	 arise	from	the	precursors	NF-κB1	(p105)	and	NF-κB2	(p100),	 respectively,	and	are	repressors	unless	bound	to	secondary	proteins.	The	two	paradigmatic	dimers	are	p50:p65	and	p52:RelB.	In	 resting	 state,	 NF-κBs	 are	 primarily	 located	 in	 the	 cytoplasm	 due	 to	 the	 binding	 of	
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inhibitory	 proteins	 (IκBs)74.	 IκBs	 contain	 five	 to	 seven	 tandem	 ankyrin	 repeats	 (AnkRs),	which	 extend	 as	 helices	 capable	 of	 binding	 to	 NF-κB	 covering	 the	 nuclear	 localization	sequence	(NLS).	Biochemical	control	of	NF-κB	subcellular	 localization	enables	IκB	to	be	a	principle	regulator	of	NF-κB	target	gene	expression,	 in	another	sense,	 it	provides	a	rapid	molecular	switch	for	responses	to	pathogens	or	inflammatory	stimuli75.	
Classical	and	alternative	NF-κB	pathways	NF-κB	 can	 be	 activated	 via	 two	 pathways:	 Canonical/classical	 and	 Non-canonical/alternate	pathways,	depends	on	the	presence	or	absence	of	IKKγ	74,76-78	(Fig.	1.2).	The	classical	pathway	is	mediated	by	p50,	RelA,	and/or	c-Rel	in	response	to	stimuli	such	as	ligation	 of	 Toll-like	 receptors	 (TLRs),	 TNFR,	 or	 IL-1R.	 As	 a	 result,	 the	 classical	 pathway	induces	expression	of		inflammatory	cytokines	and	chemokines	such	as	IL-	1β,	TNFα,	IL-6,	and	IL-879.	Upon	stimulation,	 the	 first	steps	of	NF-κB	activation	 involves	phosphorylation	and	ubiquitin	modification	of	IκB	inhibitors;	this	occurs	primarily	via	activation	of	IκB	kinase	(IKK).	 IKK	 is	 composed	 of	 a	 heterodimer	 of	 the	 catalytic	 IKKα	 and	 IKKβ	 subunits	 and	 a	"master"	regulatory	protein	 termed	NEMO	(NF-κB	essential	modulator)	or	 IKKγ.	The	IKK	phosphorylates	two	serine	residues	(e.g.,	serines	32	and	36	in	human	IκBα)	located	in	an	IκB	regulatory	domain,	phosphorylation	of	IκB	is	followed	by	ubiquitination	and	proteasomal	degradation.	Once	released	from	IκB,	NF-κB	dimers	are	able	to	stay	in	the	nucleus	and	induce	gene	expression.	Those	genes	include	chemokines,	cytokines,	inflammatory	mediators,	and	apoptosis	inhibitors,	all	of	which	play	pivotal	roles	in	both	innate	and	adaptive	immunity.		A	subset	of	TNF	superfamily	members	such	as	lymphotoxin	β80-82,	CD4083,	and	B	cell-activating	factor	(BAFF)84	induces	NF-κB	through	an	alternative	pathway.	In	this	pathway,	a	dimer	 of	 IKKα	 specifically	 phosphorylates	 p100	 on	 serines	 176	 and	 180,	 causing	
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proteasomal	 processing	 to	 p5274,85.	 Activation	 of	 IKKα	 is	 dependent	 on	 NF-κB	 inducing	kinase	(NIK),	which	is	then	detached	from	the	TRAF	complex.	In	contrast	to	the	canonical	pathway,	which	 responds	 rapidly	 to	 ligand	 stimulation,	 the	 alternative	pathway	 requires	new	protein	synthesis	therefore	has	slow	and	sustained	kinetics,	this	is	consistent	with	its	role	in	organogenesis74,75.			
		
Figure	1.2	Classical	and	alternate	NF-κB	pathways.	The	classical	pathway	is	activated	by	ligation	of	Toll-like	 receptors	 (TLRs),	TNFR,	or	 IL-1R,	 followed	by	 the	activation	of	 IKK	complex.	The	 IκB	kinase	phosphorylates	two	serine	residues	located	in	an	IκB	regulatory	domain,	resulting	in	its	ubiquitination	degradation.	 p50/RelA	 dimers	 then	 translocate	 to	 the	 nucleus,	 bind	 κB	 sites	 and	 initiate	 target	 gene	transcription.	The	alternative	pathway	induced	by	detachment	of	NIK	from	cIAP-TRAF	complex.	Active	NIK	 phosphorylates	 IKKα,	 activated	 IKKα	 dimers	 can	 then	 phosphorylate	 p100,	 resulting	 in	 its	ubiquitination	and	processing	to	p52.	p52/RelB	can	then	drive	their	target	gene	transcription.	
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The	role	of	TNFR1	in	NF-κB	signaling	transduction	Tumor	necrosis	factor	alpha	(TNFα)	is	one	of	the	19	TNF	superfamily	members,	and	it	 is	 a	master	 activator	 of	 NF-κB.	 TNFα	 is	 produced	 by	 a	 variety	 of	 cell	 types,	 including	activated	macrophages,	CD4	and	CD8	lymphocytes,	NK	cells,	neutrophils,	as	well	as	tumor	cells.	The	receptors	that	bind	to	TNFα	are	members	of	the	tumor	necrosis	factor	receptor	superfamily	TNFR1	(TNF	receptor	type	1;	CD120a;	p55/60)	and	TNFR2	(TNF	receptor	type	2;	CD120b;	p75/80).	TNFR1	is	ubiquitously	expressed	 in	most	 tissues	and	 is	 the	primary	responder	 to	 the	 soluble	 trimeric	 forms	 of	 TNFα,	 whereas	 TNFR2	 is	 typically	 found	 in	immune	 cells	 and	 responds	 to	 the	membrane-bound	 form	 of	 the	 TNF	 homotrimer.	 Both	TNFR1	 and	 TNFR2	 contain	 an	 extracellular	 domain,	 a	 transmembrane	 segment,	 and	 an	intracellular	domain	(Fig.	1.3).	TNFR1	and	TNFR2	commonly	contain	cysteine-rich	domains	(CRD)	 in	 their	extracellular	part,	 the	difference	of	 their	 intraocular	segment	 indicates	 the	two	receptors	play	distinct	roles	in	transducing	TNFα	signals	86,87.	TNFR1	contains	a	death	domain	(DD)	in	its	intracellular	segment.	Binding	of	TNFα	results	in	the	trimerization	of	the	TNFR1	receptor,	and	the	rapid	recruitment	of	downstream	adaptor	proteins	 to	 the	death	domains	in	the	cytoplasmic	region	of	the	TNFR1.	In	contrast,	TNFR2	does	not	contain	death	domains,	and	soluble	TNFα	exhibits	low	affinity	for	TNFR2	therefore	does	not	induce	strong	signaling	88.			 Two	contradictory	downstream	pathways	can	be	activated	by	TNFR1	upon	binding	of	ligand:	the	survival	promoting	signaling	that	is	primarily	mediated	through	expression	of	inflammatory	cytokines,	the	apoptotic	and	necrotic	signaling	that	induce	cell	death	(Fig.	1.4).	The	regulation	of	the	balance	between	these	two	pathways	is	dependent	on	many	factors	
	18 
such	as	cell	and	tissue	type,	microenvironment,	the	composition	of	adaptor	protein	complex,	the	concentration	of	complex	inhibitors	of	apoptosis	proteins	(cIAP),	and	the	level	of	NF-κB	expression89.			
		
Figure	1.3	TNFR1	and	TNFR2.	TNFR1	and	TNFR2	are	characterized	by	cysteine-rich	domains	(CRD)	in	their	 extracellular	domain.	TNFR1	 contains	 a	death	domain	 (DD)	 in	 its	 intracellular	domain,	whereas	TNFR2	contains	TRAF2	binding	site	(T2bs).	Binding	of	ligand	leads	to	the	formation	of	trimerization	of	the	receptors.			 On	 the	 other	 hand,	 NF-κB	 activity	 needs	 to	 be	 tightly	 regulated	 to	 ensure	 the	maintenance	of	tissue	homeostasis.	Uncontrolled	activation	of	the	innate	immune	response	through	prolonged	NF-κB	activity	can	cause	chronic	inflammation	and	autoimmune	diseases.	Tumor	necrosis	 factor	 alpha-induced	protein	3	 (TNFAIP3),	 also	 referred	 to	 as	A20,	 is	 an	ubiquitin-editing	 enzyme	 the	 expression	of	which	 is	 rapidly	 induced	by	TNFα90.	A20	has	been	 implicated	 in	 negatively	 regulating	 NF-κB	 activity	 in	 multiple	 actions	 through	 its	ubiquitin-regulatory	 activity91.	 Receptor-interacting	 protein-1	 (RIP-1),	 also	 known	 as	receptor-interacting	serine/threonine	kinase	1	(RIPK1)	is	a	kinase	upstream	of	the	NF-κB	signaling	cascade	(further	discussed	in	page	17).	Polyubiquitination	at	lysine63	(K63)	of	RIP-1	by	E3	ligase	cIAP1	after	TNFα	stimulation	is	an	essential	step	activates	TAK1	and	IKK.	A20	
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removes	 this	 polyubiquitin	 chains	 from	 RIP1	 K63	 and	 subsequently	 adds	 K48-linked	polyubiquitin	 chains	 to	 RIP1,	 targeting	 it	 for	 proteasomal	 degradation.	 This	 sequential	deubiquitination	 and	ubiquitin-mediated	degradation	of	RIP1	prevents	 the	 interaction	 of	NF-κB	 essential	modulator	 (NEMO)	with	 RIP1,	 therefore	 restricts	 TNF	 stimulated	NF-κB	activation	 92.	A20	can	also	 restrict	TLR4	and	nucleotide-binding	oligomerization	domain-containing	 protein	 2	 (NOD2)-induced	 NF-κB	 activity	 by	 deubiquitinating	 TNF	 receptor-associated	factor	TRAF6	and	RIP2,	respectively	93,94.	Furthermore,	Shembade	et	al.	revealed	the	mechanism	 by	which	 A20	 inhibits	 the	 E3	 ligase	 activity	 of	 cIAP1;	 it	 antagonizes	 the	interactions	 between	 E3	 and	 E2	 ubiquitin	 conjugating	 enzymes	 (Ubc13	 and	 UbcH5c).	Additionally,	A20	promotes	the	proteasomal	degradation	of	Ubc13	and	UbcH5c	through	the	addition	of	K48-linked	ubiquitin	chains.	A	similar	mechanism	was	also	found	in	TNF-induced	NF-κB	signaling	95.		
TNFR1-induced	survival	and	apoptosis	signaling	Upon	ligand	(TNFα)	binding,	the	trimerization	of	TNFR1	leads	to	dissociation	of	the	silencer	of	death	domain	(SODD)	from	the	intracellular	death	domain,	a	process	that	further	enables	 TNFR1-associated	 death	 domain	 (TRADD)	 recruitment	 to	 TNFR1	 due	 to	 DD–DD	interactions.	TRADD	is	an	adaptor	protein	and	serves	as	a	platform	for	subsequent	protein	binding.	 TNFR-associated	 factor	 2	 (TRAF2),	 and	 receptor	 interacting	 protein-1	 (RIP-1)	interact	 directly	with	 TRADD.	 RIP-1	was	 found	 to	 be	 indispensable	 for	 NF-κB	 activation	according	to	studies	using	RIP-deficient	Jurkat	cells	and	RIP	-/-	mice	96,97,	whereas	TRAF2	deficiency	only	caused	delay	and	slight	reduction	of	TNF-induced	NF-κB	activation	98.	Later	on,	it	was	found	that	TRAF2	is	primarily	responsible	for	the	recruitment	of	IKK	to	TNFR1	in	response	to	TNF	treatment.	The	rapid	recruitment	of	IKK	to	the	TNF-R1	signaling	complex	
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allows	IKK	to	be	efficiently	activated.	In	contrast,	RIP	does	not	recruit	IKK,	but	its	presence	in	the	same	receptor	complex	is	crucial	for	TNF-induced	IKK	activation	99.	These	proteins	form	 the	 membrane-bound	 TNFR1–TRADD–RIPK1–TRAF2	 signaling	 core,	 which	 is	 also	known	as	signal	complex	I;	this	complex	is	able	to	activate	IKK	and	further	activate	NF-κB	and	 promote	 its	 translocation	 to	 the	 nucleus.	 Hence,	 TNFα	 induces	 cell	 survival	 and	proliferation,	 inflammatory	 response,	 and	 anti-apoptotic	 factors	 (Fig.	 1.4).	 During	 the	process	of	signal	complex	I	activation	through	polyubiquitination,	cIAP1/2	not	only	function	as	E3	ubiquitin	ligases,	but	are	also	responsible	for	the	recruitment	of	the	linear	ubiquitin	chain	 assembly	 complex	 (LUBAC),	 all	 of	 these	 ensures	 RIP-1	 mediated	 TAK1	 and	 IKK	activation	100.	In	addition	to	NF-κB	activation,	Signal	complex	I	also	activates	transcription	factor	Activator	protein	1	(AP-1)	via	MAPK	p38	and	c-Jun	N-terminal	kinase	(JNK),	regulates	expression	 of	 another	 sets	 of	 genes	 involved	 in	 cell	 proliferation,	 differentiation	 and	apoptosis101-104.	 	Molecular	 events	 via	 signal	 complex	 I	 occur	 transiently	 and	 allow	 production	 of	functionally	relevant	amounts	of	NF-κB	regulated	proteins	in	less	than	1	h105,106.	Once	this	rapid	response	is	complete,	TNFR1	is	internalized.	Signal	complex	I	is	then	dissociated	from	the	 receptor	 death	 domain	 and	 released	 into	 the	 cytoplasm;	 after	 binding	 of	 the	 Fas-associated	 death	 domain	 protein	 (FADD),	 caspase-8,	 and	 RIPK3,	 this	 receptor-free	cytoplasmic	complex	becomes	complex	IIa	and	IIb.	The	induction	of	apoptosis	or	necroptosis	by	complex	IIa	or	IIb	is	context	dependent;	cleavage	of	apoptosis	effector	caspases	(caspases	3/7)	 requires	 recruitment	 of	 a	 high	 concentration	 of	 caspase-8	 and	 its	 autoproteolytic	activation	(Fig.	1.4).	If	activation	of	caspase	8	is	inhibited,	necroptosis	will	occur	due	to	the	formation	of	necroptosis-inducing	oligomeric	RIPK1/RIPK3	aggregates106-108.		
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Figure	1.4.	TNFα	receptor	and	NF-κB	signaling.	The	right	side	of	the	diagram	shows	activation	of	NF-κB	 via	 TNFR1–TRADD–RIPK1–TRAF2	 signaling	 core	 (signal	 complex	 I),	 which	 induces	 expression	 of	genes	 that	 are	 associated	with	 survival,	 inflammation,	 and	 immune	 surveillance.	 The	 left	 side	 of	 the	diagram	shows	internalization	of	TNFR1,	which	results	in	dissociation	of	signal	complex	I	from	receptors	and	formation	of	a	cytoplasmic	complex	that	induces	caspase	8-mediated	apoptosis.		 Evidence	indicate	extensive	cross-talk	between	the	conflicting	survival	and	apoptotic	signaling	 transduced	 by	 TNFR1.	 On	 one	 hand,	 NF-κB	 enhances	 the	 transcription	 of	 anti-apoptotic	 proteins	 including	 Bcl-2	 family,	 c-FLIP	 and	 cIAPs.	 Bcl-2	 family	 constrains	 the	activation	 of	 apoptotic	 proteins	 BAX/BAK	 therefore	 prevents	 mitochondrial	 outer	membrane	permeabilization	and	the	releasing	of	cytochrome	c	to	form	the	caspase	cascade.		c-FLIP	 is	 a	 caspase	 8	 inhibitor	 that	 is	 responsible	 for	 resistance	 to	 FAS	 Ligand	 or	 TNFα	
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induced	apoptosis,	cIAPs	can	directly	bind	caspases	to	inhibitor	their	functions.	On	the	other	hand,	activated	caspases	cleave	several	components	of	the	NF-κB	pathway	such	as	RIP,	IKK,	as	well	as	NF-κB	subunits.	109.	All	those	tightly	regulated	signaling	ensures	the	appropriate	downstream	 targets	 and	 cellular	 functions	 are	 correctly	 triggered	 rapidly	 upon	 TNFα	stimulation.		Because	 TNFR1	 is	 internalized	 rapidly	 upon	 ligand	 binding,	 it	 is	 inferred	 that	promoting	 TNFR1	 membrane	 translocation	 or	 enhancing	 its	 membrane	 retention	 will	enhance	the	signal	intensity	and	sustainability.	Similar	to	many	other	membrane	receptors,	newly	translated	TNFR1(p55/cd120a)	protein	is	subject	to	post-translation	modifications	in	the	endoplasmic	reticulum	and	is	then	translocated	to	the	cell	surface	via	the	Golgi	complex.	How	the	post	translational	modifications	will	impact	the	localization	of	TNFR1	protein,	and	what	 biochemical	 events	 are	 driving	 the	 TNFR1	 translocation	 is	 not	 fully	 understood.	Previous	 studies	 implicated	 a	 membrane	 localization	 regulatory	 role	 for	 ERK	phosphorylation	 sites	 in	 the	TNFR1	 transmembrane	domain110.	 The	 authors	used	 a	GST-CD120a-(207–425)	 fusion	 protein	 and	 ex	 vivo	 system	 to	 demonstrate	 that	 cytoplasmic	domain	of	TNFR1	contains	multiple	sites	that	can	be	phosphorylated	by	p42	MAPK1/ERK2.	As	a	consequence	of	phosphorylation,	TNFR1	protein	translocation	at	the	plasma	membrane	and	 Golgi	 apparatus	 was	 lost,	 instead,	 the	 receptor	 was	 constrained	 in	 endoplasmic	reticulum	tubular	structures,	resulting	in	the	accumulation	of	intracellular	TNFR1	protein.	The	authors	also	identified	4	phosphorylation	sites,	the	preferred	sites	being	Thr-236	and	Ser-270.	 Primary	 phosphorylation	 at	 these	 sites	 appeared	 to	 enable	 subsequent	phosphorylation	 at	 Ser-240	 and	 Ser-244110,111.	 In	 addition,	 multiple	 sites	 at	 the	transmembrane	region	are	predicted	to	be	ERK	phosphorylation	sites,	suggesting	regulation	
	23 
of	 TNFR1	 sub-cellular	 compartment	 localization.	 However,	 it	 is	 not	 known	 if	phosphorylation	of	TNFR1	also	occurs	in	vivo.	This	aspect	will	be	further	discussed	in	the	fourth	chapter	of	this	dissertation.			
	Cancer	immune	surveillance,	cytokines,	and	immune	therapy	
The	roles	of	TNFα	and	IFNγ	in	cancer	immune	surveillance	Our	 host	 immune	 system	 plays	 indispensable	 roles	 in	 suppressing	 cancer	development	as	well	as	anti-cancer	treatment	response.	The	concept	of	immune	surveillance	against	tumor	cells	was	first	proposed	in	the	1950s.	It	was	initially	hypothesized	by	several	scientists	that	the	immune	system	can	recognize	newly	arising	tumors	and	eliminate	them	through	tumor-specific	antigen	recognition112,113.	It	is	now	known	that	professional	antigen-presenting	 cells	 (APCs)	 process	 and	 present	 tumor-associated	 antigens	 to	 immune	 cells,	therefore	prime	T	cells	into	effector	cells.	Effector	T	cells	migrate	toward	the	tumor	loci	and	upon	cognate	antigen	recognition	kill	the	tumor	cells.	T	cell	presence	in	tumors	is	typically	indicative	of	immune	surveillance	and,	as	such,	is	strongly	associated	with	improved	patient	survival	in	multiple	malignancies114-119.	Immune	surveillance	in	the	steady	state	relies	on	the	activity	 of	 relatively	 few	 immune	 signaling	 pathways120,121,	 crucial	 amongst	 them	 is	 the	pathway	 regulated	 by	 the	 cytokine	 IFNγ,	 a	 type	 II	 interferon.	 Studies	 using	 mice	 with	targeted	 mutations	 in	 the	 IFNγ	 pathway	 have	 established	 its	 essential	 role	 in	 immune	surveillance	through	induction	of	Th1	polarization	and	effector	lymphocyte	activation.		The	direct	tumor	cytotoxicity	of	killer	dendritic	cells	has	also	been	shown	to	be	IFNγ	dependent	
122-126.	 Furthermore,	 gene	 expression	 signatures	 associated	 with	 sensitivity	 to	immunotherapy	are	strongly	associated	with	IFNγ	pathway	activity127,128.	
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Another	 pathway	 associated	 with	 the	 response	 to	 immunotherapy	 is	 the	 TNFα	pathway128.	 In	 the	 tumor	 microenvironment,	 TNFα	 is	 produced	 by	 NK	 cells,	 CD4	lymphocytes,	and	certain	CD8	lymphocytes	upon	activation	by	antigens	or	mitogens129.	In	addition,	tumor	cells	can	also	produce	TNFα	through	NF-κB-regulated	transcription.	It	was	mentioned	 in	 a	 previous	 section	 that	 NF-κB	 can	 activate	 the	 transcription	 of	 abundant	immune	 regulatory	 genes.	 Notably,	 a	 host	 of	 immune	 function	 genes	 are	 jointly	 and	synergistically	 regulated	 by	 both	 TNFα	 and	 IFNγ,	 therefore	 profoundly	 impacting	 tumor	immunity	 through	 several	 important	 aspects,	 including	 transcription	 regulation	 of	major	histocompatibility	complex	(MHC)	molecules,	T	cell	receptor	(TCR)	signaling	molecules,	and	T	 cell	 chemokines	 (CXCL9/10/11),	 all	 of	 which	 are	 responsible	 for	 T	 cell	 activation,	migration,	and	infiltration20,130,131.		
TNFα	and	IFNγ	regulate	immune	surveillance	genes	involved	in	T	cell	activation		 Major	histocompatibility	complex	(MHC)	molecule	expression	is	strongly	regulated	by	TNFα	and	IFNγ.	There	are	three	types	of	MHC:	class	I,	II,	and	III;	MHC	class	I	and	II	are	well	 studied	and	known	 to	determine	 the	diversity	of	 antigen	presentation.	MHC	class	 II	contains	 α1,	 α2,	 β1,	 and	 β2	 subunits	 and	 normally	 expressed	 only	 on	 APCs	 such	 as	macrophages,	B	cells,	and	especially	dendritic	cells	(DCs).	MHC	class	II	can	be	recognized	by	CD4	TCR	and	co-receptors	to	prime	helper	T	lymphocytes.	Class	I	MHC	molecules	have	α1-3	and	β2	microglobulin	subunits	and	are	expressed	in	all	nucleated	cells.	In	humans,	MHC	class	I	 comprises	 HLA-A,	 HLA-B,	 and	 HLA-C	 molecules.	 Abundant	 expression	 of	 class	 I	 MHC	antigens	on	tumor	cells	is	required	for	the	host	immune	system	to	recognize	and	reject	them	
132.	 MHC	 class	 I	 binds	 to	 CD8	 TCR	 and	 co-receptors,	 presenting	 epitopes	 to	 cytotoxic	 T	lymphocytes	 (CTLs).	CTL	 induces	 cytotoxicity	of	 infected	or	malignant	host	 cells	 through	
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perforins,	granzymes,	and	Fas.	Among	numerous	transcription	factors	that	are	responsible	for	 the	 expression	 of	MHC	 I	 genes,	 IFNγ	 and	 TNFα	 are	 the	 two	 of	most	 important	 ones,	interestingly,	they	both	individually	and	corporately	regulate	the	MHC	I	transcription.	IFNγ	induces	 strong	 and	 steady	MHC	 I	 expression	via	 the	 JAK/STAT	pathway133-137.	 Cells	with	enhanced	MHC	I	expression	may	be	better	recognized	and	targeted	by	CTLs.	TNFα	has	also	been	shown	to	upregulate	constitutively	expressed	HLA	genes	in	different	tumor	cell	lines138	and	several	neoplastic	cell	 lines	of	carcinoma	and	 leukemia	origin139.	 In	contrast	 to	 IFNγ,	TNFα	 does	 not	 induce	 de	 novo	 expression	 of	 HLA	molecules	 but	 acts	 as	 an	 enhancer	 of	constitutive	or	IFNγ-induced	HLA	gene	expression,	given	that	enhancers	of	HLA-A,	B	genes	were	 found	 to	 contain	NF-κB-binding	motifs140.	 Additionally,	 TNFα	may	 increase	 the	 cell	surface	stability	of	MHC	I	141.	IFNγ	and	TNFα	also	indirectly	regulates	MHC	I	gene	expression	through	 inducing	other	 transcription	 factors	 that	bind	 to	distinct	 cis-elements	 regulating	MHC	I	gene	expression142-144.	Those	evidence	explain	the	joint	regulatory	role	of	IFNγ	and	TNFα	on	the	expression	of	MHC	class	I,	 therefore,	combined	treatment	of	 IFNγ	and	TNFα	may	result	in	increased	tumor	immunogenicity	due	to	the	synergistic	expression	of	HLA.	This	is	especially	importance	for	those	tumor	cells	of	which	baseline	HLA	antigens	expression	is	low	 and	 thus	 are	 resistant	 to	 cytotoxic	 actions	 of	 CTLs145.	 IFNγ	 and	 TNFα	 synergy	 also	induces	high	expression	of	a	host	of	other	immune	function	genes,	as	discussed	below.	In	addition	to	TCR	signaling	triggered	by	recognition	of	cognate	antigenic	peptides	presented	by	MHC	molecules,	the	fate	of	effector	T	cells	is	also	under	regulation	of	a	second	signaling	from	co-receptors,	which	can	be	either	stimulatory	or	inhibitory.	The	discovery	of	CD28	as	a	prototype	co-stimulatory	TCR	provided	evidence	for	the	two-signal	model	of	T	cell	activation,	the	second	signaling	process	having	a	critical	role	in	the	maintenance	of	immune	
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homeostasis146-148.	The	binding	of	CD28	to	its	ligand	(B7-1/2,	aka	CD80/86)	produces	a	co-stimulatory	 signal	 including	 activation	 of	 MEK	 and	 AKT	 pathways,	 apoptosis	 inhibitor	protein	family	Bcl-xL,	and	downregulation	of	cell	cycle	inhibitor	p27(kip1),	all	of	which	are	required	for	the	 fully	activation	of	T	cells	149.	 In	contrast,	co-inhibitory	receptors,	such	as	CTLA-4	and	PD-1	trigger	signaling	that	dampens	T	cell	activation	signaling	and/or	promotes	the	 function	 of	 regulatory	T	 (TReg)	 cells,	which	 suppress	 CTL	 functions.	 In	 recent	 years,	blockade	of	inhibitory	signaling	induced	by	CTLA-4	and	PD-1	has	achieved	significant	clinical	success	and	become	the	cutting	edge	of	anti-tumor	immune	therapy	(discussed	in	previously	in	page	2	and	6).	Those	encourage	 results	has	 triggered	extensive	 investigation	 interests	focus	 on	 identifying	 other	 targetable	 co-inhibitory	 receptors	 to	 broaden	 the	 therapeutic	repertoire.	Lag-3,	Tim-3,	and	TIGIT	comprise	the	next	generation	of	promising	co-inhibitory	receptors	to	be	translated	to	the	clinic.	IFNγ	was	found	to	strongly	induce	expression	of	PD-L1,	PD-L2	(ligands	of	PD-1),	CD80,	and	CD86	(ligands	of	CD28	or	CTLA-4)	in	multiple	types	of	tumors150-152.	Studies	using	patient	biopsies	and	mouse	models	have	found	the	loss	of	IFNγ	pathway	 signaling	 as	 a	 mechanism	 of	 resistance	 to	 anti-PD1	 and	 anti-CTLA-4	therapy127,153,154.	 TNFα	 induces	 RNA	 and	 protein	 expressions	 of	 PD-L1	 mainly	 through	activating	the	NF-κB	and	ERK1/2	signaling	pathways155.	Synergistic	upregulation	of	PD-1	ligands	by	IFNγ	and	TNFα	was	observed	in	acute	myeloid	leukemia	(AML)156;	on	the	other	hand,	IFNγ	and	TNFα	may	also	cooperatively	suppress	PD-L1	expression	through	induction	of	miRNA-155157.	
TNFα	and	IFNγ	regulate	immune	surveillance	genes	involved	in	T	cell	chemotaxis	For	solid	tumors,	the	benefit	from	immunotherapy	is	typically	associated	with	high	pre-treatment	expression	of	immune	surveillance	genes	and	T	cell	infiltration14,158,159.	The	
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migration	 of	 T	 cells	 into	 the	 tumor	microenvironment	 is	 a	 highly	 dynamic	 process	 that	involves	multiple	regulatory	molecular	events	include	rolling,	adhesion,	extravasation,	and	chemotaxis160,161.	 Chemotaxis	 is	 a	 coordinated	 process	 of	 T-cell	movement	 that	 requires	chemokines,	 and	 their	 chemokine	 receptors,	 to	 invoke	 signaling	 events	 to	 direct	 cell	migration.	Chemokines	are	classified	 into	 four	groups	 (CC,	CXC,	C	and	CX3C	chemokines)	based	on	the	first	two	cysteine	residues,	each	type	of	chemokines	bind	to	their	corresponding	receptors	(CCR,	CXCR,	XCR1	and	CX3CR1).	CXC	Motif	Chemokine	Receptor	3	(CXCR3)	is	one	of	the	major	chemokine	receptors	found	to	be	expressed	by	activated	TILs	in	multiple	types	of	cancer	including	melanoma,	colorectal,	and	breast	cancers,	suggests	the	important	roles	of	 its	 ligand	 chemokines	 in	CTL	 trafficking	 to	 the	 tumor	microenvironment162-165.	 CXCL9,	CXCL10,	and	CXCL11	are	the	ligands	of	CXCR3	and	are	commonly	produced	by	local	cells	in	inflammatory	 lesions	or	 in	 the	 tumor	microenvironment.	Binding	of	 those	chemokines	 to	CXCR3	induces	various	cellular	responses	of	T	cells	including	integrin	activation,	cytoskeletal	changes,	and	chemotactic	migration.	Consistent	with	patient	studies,	 in	murine	models	of	solid	cancer,	CXCR3+	CTL	infiltration	is	positively	associated	with	increased	expression	of	CXCL9	 and	 CXCL10	 by	 tumor	 cells,	 as	 well	 as	 enhanced	 antitumor	 response20,166-168.	Insufficient	expression	of	CXCR3	may	reduce	the	recruitment	of	effector	T	cells;	however,	the	recruitment	could	be	improved	through	upregulation	of	the	ligands	(i.e.	CXCL9,	CXCL10,	and	CXCL11),	which	are	all	 IFNγ	inducible169;	 therefore	IFNγ	production	from	active	TILs	may	reinforce	the	CXCR3-mediated	T-cell	recruitment	to	the	tumor	site.		TNFα	 also	 induces	 expression	 of	 T	 cell	 chemokines,	 primarily	 through	 NF-κB	regulated	transcription.	High	expression	of	NF-κB-regulated	genes	that	may	be	involved	in	T-cell	responses,	for	instance,	(C-C	motif)	ligand	2	(CCL2),	intercellular	adhesion	molecule	1	
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(ICAM1),	 and	 lymphotoxin	β	 (LTB)	was	associated	with	 improved	disease	outcome170,171.	CCL2	is	also	referred	to	as	monocyte	chemoattractant	protein	1	(MCP1)	and	small	inducible	cytokine	A2,	and	it	belongs	to	the	CC	chemokine	family.	CCL2	recruits	monocytes,	memory	T	cells,	and	dendritic	cells	to	the	sites	of	inflammation	and	is	produced	by	either	tissue	injury	or	infection172,173.	Another	CC	chemokine	family	member	is	CCL5,	which	is	chemotactic	for	T	cells,	 eosinophils,	 and	 basophils,	 and	 plays	 an	 active	 role	 in	 recruiting	 leukocytes	 into	inflammatory	sites20,171.		Importantly,	 evidence	 has	 shown	 that	 TNFα	 and	 IFNγ	 together	 synergistically	regulate	 a	 set	 of	 T	 cell	 chemokines	 including	 CCL2,	 CCL5,	 and	 CXCL9-11174,175.	 Previous	research	 in	our	 laboratory	 in	a	 lung	cancer	murine	model	showed	 that	 inducing	of	T	cell	chemokine	 expression	 through	 combining	 HDAC	 inhibitors	 with	 immune	 checkpoint	blockade	enhanced	T	cell	infiltration	and	the	anti-tumor	effects	of	activated	T	cells	both	in	vitro	and	in	vivo20,176.	Those	co-regulated	T	cell	chemokines	have	also	been	shown	to	belong	to	 a	 set	 of	 tumor	 immune	 surveillance	 signatures	 and	 are	 positive	 prognostics/response	predictors170,171,177.	
TNFα	and	IFNγ	induce	tumor	cell	cycle	arrest,	apoptosis,	and	senescence	In	 addition	 to	 immune	 surveillance,	 T	 cell	 cytokines	 contribute	 to	 the	 antitumor	activity	 of	 T	 cells	 by	 inducing	 proliferative	 arrest	 and/or	 apoptosis.	 Despite	 the	 tumor-promoting	potential	due	to	inflammatory	signaling	triggered	by	TNFα,	the	property	of	TNFα	in	 inducing	 cancer	 cell	 death	 through	 apoptosis	 (discussed	 in	 page	 17-19)	 renders	 it	 a	potential	 cancer	 therapeutic,	 and	 it	 was	 explored	 extensively	 for	 clinical	 use	 years	 ago;	however,	 the	 toxicity	 for	 systemic	 TNFα	 administration	 has	 restricted	 its	 practical	application.	 Recent	 studies	 have	 focused	 on	 sensitizing	 cancer	 cells	 to	 TNF-induced	
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apoptosis	via	caspase	8;	this	sensitization	can	be	achieved	by	inhibiting	the	survival	signal	arm	 mediated	 by	 TRAF2/cIAP1,	 and	 this	 strategy	 can	 further	 enhance	 the	 anti-tumor	efficacy	of	immune-checkpoint	blockade178.	IFNγ	 is	 also	 known	 to	 directly	 suppress	 tumor	 growth	 through	 a	 variety	 of	mechanisms.	although	not	all	types	of	tumors	are	susceptible	to	IFNγ,	in	cancer	types	such	as	 breast	 cancer179,	 colorectal	 cancer180,	 and	 hepatocellular	 cancer181,	 IFNγ	 suppresses	tumor	cells	proliferation	via	enhancing	expression	of	the	cell	cycle	inhibitor	proteins	p27Kip,	p16,	 or	 p21182-184.	 Moreover,	 in	 colorectal	 cell	 lines,	 IFNγ	 induces	 mitochondria-derived	reactive	oxygen	species	(ROS),	which	is	dependent	on	cytosolic	phospholipase	A2	(cPLA2)	activation,	as	a	result,	the	target	cells	undergo	autophagy-associated	apoptosis	185.	Recent	study	 also	 showed	 a	 novel	 synergistic	 necroptosis	 induction	 effect	 of	 IFNγ	when	 it	 is	 in	combined	with	 second	mitochondria-derived	 activator	 of	 caspases	 (Smac)	mimetics,	 this	combination	antagonizes	the	x-linked	inhibitor	of	apoptosis	(XIAP),	and	induces	necroptosis	in	apoptosis-resistant	cancer	cells	that	are	lack	of	caspase	activity.	This	synergistic	effect	is	not	only	observed	in	solid	and	hematological	cancer	cell	lines,	but	also	found	generalizable	for	different	Smac	mimetics186,187.	In	pancreatic	β-cells,	treatment	with	TNFα	and	IFNγ	induced	apoptosis	via	activation	of	the	proapoptotic	protein	Bim	(Bcl-2	family	member)	that	occurred	in	a	STAT1-dependent	manner188.	In	contrast,	downregulation	of	the	antiapoptotic	Bcl-xL	protein	by	TNFα	and	IFNγ	sensitized	 colon	 carcinoma	 cells	 to	 TRAIL-mediated	 apoptosis189.	 Other	 studies	 also	demonstrated	that	the	presence	of	TNFα	and	IFNγ	can	synergistically	induce	cell	cycle	arrest,	leading	 to	 senescence	 or	 apoptosis,	 a	 response	 that	 requires	 TNFR1	 and	 STAT1/IRF1	signals190,191.		
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Current	immune	therapy	strategies	and	challenges	Ever	since	the	concept	of	immune	surveillance	was	proposed	and	widely	accepted,	researchers	 have	 begun	 to	 develop	 therapeutics	 that	 exploit	 the	 host	 immune	 system	 to	combat	cancers.	Decades	of	endeavors	have	resulted	in	both	failures	and	successes.	Although	the	 early	 strategies	 such	 as	 IL-2	 treatment	 and	 dendritic	 cell	 vaccines	 did	 not	 bring	meaningful	clinical	impact,	our	evolving	understanding	of	the	host	immune	system	over	the	past	few	years	has	led	to	fruitful	new	strategies.	The	most	significant	advances	in	immune	therapy	have	been	immune	checkpoint	blockade	inhibitors,	which	enhance	the	endogenous	antitumor	immune	response	by	blocking	inhibitory	signals	(discussed	in	page	25).		Recently,	 combination	 of	 anti-PD-1	 and	 anti-CTLA-4	 therapies	 in	 treatment-naive	metastatic	 melanoma	 (CHECKMATE-067)	 has	 demonstrated	 a	 synergistic	 survival	advantage	 over	 either	 monotherapy192.	 Subsequently,	 combinatory	 approaches	 among	immune	checkpoint	blockade	therapies	and	with	other	drugs	have	been	actively	tested	in	clinic.	 For	 example,	 pembrolizumab	 plus	 dabrafenib	 and	 trametinib	 is	 currently	 under	evaluation	in	BRAF-mutant	advanced	melanoma	(KEYNOTE-022)193.	This	approach	is	based	on	 evidence	 from	 preclinical	 studies	 and	 clinical	 biopsy	 analyses	 showing	 that	 targeting	RAS/RAF/MEK	signaling	creates	a	tumor	microenvironment	that	enhances	the	response	to	immunotherapy	(discussed	in	page	12),	although	the	underlying	molecular	mechanism	was	not	yet	fully	uncovered.	Based	on	the	currently	available	clinical	data	of	KEYNOTE-022	in	melanoma,	the	triple	combination	of	pembrolizumab,	dabrafenib,	and	trametinib	is	showing	improved	 and	 long-lasting	 response	 compared	 to	 the	 dabrafenib	 and	 trametinib	 doublet	group;	however,	the	triplet	group	also	exhibited	a	higher	rate	of	grade	3/4	adverse	events	
194,195.		
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Another	notable	success	of	recent	immune	therapy	is	T	cell-based	therapies.	Adoptive	transfer	of	genetically	modified	T	cells	that	express	chimeric	antigen	receptors	(CAR-Ts)	has	revolutionized	 the	 treatment	of	hematologic	malignancies196,197.	 Furthermore,	 autologous	antigen-specific	TIL	therapies	are	showing	promising	results	in	solid	tumors.	This	approach	has	distinct	 advantages	over	CAR-T	 therapies,	unlike	engineered	CAR-Ts	which	are	often	restricted	to	the	limitation	of	tumor	specific	antigens,	autologous	TILs	are	able	to	target	a	broader	range	of	both	known	and	unknown	antigens.			The	preparation	of	autologous	TILs	is	to	extract	and	enrich	tumor-specific	lymphocytes	from	peripheral	blood	or	resected	tumors,	followed	by	the	ex	vivo	expansion,	activated	autologous	TIL	are	then	reintroduced	into	the	patient	 with	 or	 without	 systemic	 lymphodepletion.	 This	 therapy	 was	 first	 succeeded	 in	melanoma198,199	and	currently	under	clinical	evaluation	of	 for	other	malignancies	such	as	head	and	neck	cancers	and	renal	cell	carcinoma	200.	The	rationale	behind	immune	therapy	for	solid	tumors	is	that	when	tumors	progress,	cancer	 cells	 produce	 an	 immunosuppressive	microenvironment,	 which	 disables	 the	 host	immunity.	 A	 variety	 of	 mechanisms	 regarding	 this	 phenomenon	 have	 been	 discussed	 in	previous	sections	of	 this	chapter	(i.e.	 inflammatory	signaling	that	represses	normal	T	cell	functions,	loss	of	MHC	expression	leading	to	tumor	cell	immune	evasion,	and	T	cell	cytokine	upregulation	of	inhibitory	signaling	ligands	such	as	PD-L1	leading	to	exhaustion	of	effector	lymphocytes).	In	addition	to	that,	some	tumors	create	a	hostile	microenvironment	for	TILs	by	depleting	nutrients	and	oxygen	and	releasing	acidic201	and	 toxic	metabolites202.	Those	findings	 indicate	 that	 simply	 reactivating	T	 cells	may	not	be	 sufficient	 to	achieve	 cure	or	sustainable	tumor	control.	Future	advances	in	anti-cancer	therapy	are	expected	to	overcome	and	resolve	many	of	these	limitations.	Anticipated	innovations	include	the	development	of	
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personalized	 biomarker	 profiles	 for	 better	 clinical	 decision-making,	 evidence-based	 drug	combination	strategies	for	improving	efficacy	(particularly	for	less	immunogenic	tumors),	and	overcoming	acquired	resistance	to	re-sensitize	cancer	cells	to	treatment.	In	this	study,	we	 attempt	 to	 shed	 a	 little	 light	 on	 those	 opportunities,	with	 a	 focus	 on	 identifying	 lung	cancer	novel	vulnerability	induced	by	MAPK	inhibitors,	thus	propose	combination	therapy	strategies	for	better	outcome.
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CHAPTER	2	–	MEK	INHIBITION	MODULATES	CYTOKINE	RESPONSE	TO	MEDIATE	
THERAPEUTIC	EFFICACY	IN	LUNG	CANCER	
Abstract	Activating	mutations	in	BRAF,	a	key	mediator	of	RAS	signaling,	are	present	in	~50%	of	melanoma	 patients.	 Pharmacological	 inhibition	 of	 BRAF	 and/or	 the	 downstream	MAP	kinase	MEK	are	highly	effective	in	the	treatment	of	BRAF	mutant	melanoma.	In	contrast,	RAS	pathway	inhibitors	have	been	less	effective	in	the	treatment	of	epithelial	malignancies,	such	as	 lung	 cancer.	We	 found	 that	 BRAF	 and	MEK	 inhibitor	 (MEKi)	 treatment	 of	 melanoma	patients	 led	to	the	activation	of	 tumor	NF-κB	activity.	 In	vitro	studies	revealed	that	MEKi	potentiates	the	response	to	TNFα,	a	potent	activator	of	NF-κB.	In	both	melanoma	and	lung	cancer	cells,	MEKi	induced	a	strong	increase	in	cell	surface	expression	of	TNFα	receptor	1	(TNFR1),	which	enhanced	NF-κB	activation	and	augmented	expression	of	genes	regulated	by	TNFα	and	IFNγ.	Screening	of	289	targeted	agents	for	the	ability	to	increase	TNFα	+	IFNγ	target	gene	expression	demonstrated	that	this	was	a	general	activity	of	 inhibitors	of	MEK	and	ERK	kinases.	Treatment	with	MEKi	led	to	the	acquisition	of	a	novel	vulnerability	to	TNFα	+	IFNγ-induced	apoptosis	in	lung	cancer	cells	that	were	refractory	to	MEKi	killing	as	well	as	the	augmentation	of	cell	cycle	arrest.	Lung	cancer	cell	knock-out	of	TNFR1	impaired	the	anti-tumor	efficacy	of	MEKi,	whereas	TNFα	+	IFNγ	administration	in	MEKi-treated	mice	enhanced	the	anti-tumor	response.	Finally,	 immunotherapeutics	known	to	 induce	 the	expression	of	these	cytokines	synergized	with	MEKi	in	eradicating	tumors.	These	findings	define	a	novel	cytokine	response	modulatory	function	of	MEKi	that	can	be	therapeutically	exploited.		
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Introduction	Activating	mutations	 in	 the	 RAS	 pathway	 comprise	 one	 of	 the	most	 common	 oncogenic	abnormalities	 in	 cancer.	 Mutations	 in	 the	 RAS	 effector	 BRAF	 kinase	 are	 present	 in	approximately	 half	 of	 all	melanoma	patients.	 Pharmacological	 targeting	 of	 BRAF	 and	 the	downstream	 MEK-ERK	 kinases	 results	 in	 significant	 benefit	 in	 BRAF	 mutant	 melanoma	patients	58,203.	This	vulnerability	 is	due	to	the	addiction	of	BRAF	mutant	melanoma	to	the	BRAF-MEK	pathway	58,204.	RAS	pathway	mutations	are	also	common	in	epithelial	tumors;	for	example,	~30%	of	 lung	 adenocarcinoma	patients	 have	mutations	 in	KRAS.	 In	 contrast	 to	
BRAF	 mutant	 melanoma,	 RAS	 pathway	 inhibitors,	 such	 as	 MEK	 inhibitors	 (MEKi),	 have	shown	limited	efficacy	in	lung	cancer	treatment	61,203,	most	likely	because	KRAS	mutations	are	not	always	associated	with	KRAS	pathway	addiction	205,206	as	well	as	the	redundancy	in	the	function	of	downstream	effector	pathways	for	cancer	cell	survival	(e.g.	MEK	and	PI3K	pathways	207-210).	New	strategies	therefore	need	to	be	developed	for	treating	KRAS	mutant	cancers.	A	 variety	 of	 approaches	 are	 being	 pursued	 to	 target	 the	 RAS	 pathway,	 including	 the	development	of	inhibitors	that	directly	target	RAS	proteins	210.	An	approach	that	has	been	pursued	for	some	time	is	the	simultaneous	targeting	of	multiple	arms	of	the	RAS	pathway,	such	 as	 PI3K-AKT	 and	 MEK-ERK	 208.	 However,	 there	 is	 concern	 about	 the	 toxicity	 of	combinations	of	 inhibitors	of	 these	pathways	 203.	 Immunotherapeutics,	particularly	 those	targeting	checkpoint	receptors	on	T	cells,	have	revolutionized	the	treatment	of	many	cancer	types.	 Interestingly,	analysis	of	melanoma	patient	biopsies	after	BRAF	and	MEK	 inhibitor	treatment	 indicate	 an	 increased	 presence	 of	 tumor	 infiltrating	 lymphocytes	 (TILs)	 67-69.	Because	patient	benefit	from	immunotherapy	is	associated	with	high	tumor	expression	of	
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immune	surveillance	genes	and	T	cell	infiltration	158,159,211,	it	has	been	proposed	that	MEKi	may	help	generate	a	tumor	microenvironment	that	enhances	response	to	immunotherapy	
64,70-72.	Indeed,	combining	MEKi	with	immunotherapy	(e.g.	T	cell	checkpoint	blockade)	in	the	pre-clinical	setting	substantially	improved	efficacy	64,70-72.	Therefore,	MEKi	may	find	use	in	combination	with	immunotherapies	in	tumor	types	that	are	otherwise	resistant	to	MEKi.		In	 previous	 studies,	 we	 found	 that	 NF-κB	 regulates	 tumor	 immune	 surveillance	 212.	 We	hypothesized	that	MEKi	may	activate	NF-κB	to	generate	a	tumor	microenvironment	that	is	more	permissive	to	immunotherapy.	In	both	human	tumors	and	in	established	cell	lines,	we	show	 that	MEKi	 enhance	expression	of	NF-κB	 target	 genes.	This	was	mediated	by	MEKi-induced	upregulation	of	cell	surface	expression	of	TNFR1,	which	strongly	potentiated	gene	expression	 responses	 by	 TNFα	 as	 well	 as	 genes	 jointly	 regulated	 by	 TNFα	 and	 IFNγ.	Furthermore,	MEKi	cooperated	with	PD-1	blockade	immunotherapy	in	curtailing	lung	tumor	growth.	A	key	and	unexpected	finding	was	the	synergy	between	MEKi	and	TNFα	+	IFNγ	in	inducing	cancer	cell	growth	arrest	and	apoptosis	across	a	broad	array	of	human	and	mouse	lung	cancer	cell	lines.	Furthermore,	cancer	cell	knockout	of	TNFR1	impaired	the	anti-tumor	activity	of	MEKi.	Such	cross-talk	between	MEKi	and	cytokine	signaling	pathways	indicates	a	novel	 mechanism	 of	 action	 for	 an	 anti-cancer	 agent	 that	 could	 be	 used	 to	 enhance	 the	therapeutic	efficacy	against	cancer	types	that	are	minimally	responsive	to	MEKi.		
Methods	and	Materials	
Cell	lines	Lung	 cancer	 and	 melanoma	 cell	 lines	 were	 provided	 by	 the	 Moffitt	 Lung	 Cancer	Center	of	Excellence	Cell	Line	Core	and	Dr.	Keiran	Smalley,	 respectively.	Cell	 lines	 tested	
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negative	 for	 mycoplasma	 contamination	 (PlasmoTest,	 Mycoplasma	 Detection	 Kit	 from	InvivoGen,	 San	 Diego,	 CA)	 and	 were	 authenticated	 by	 STR	 analysis.	 All	 lung	 cancer	 and	melanoma	 cell	 lines	 were	 maintained	 in	 RPMI	 1640	 with	 10%	 fetal	 bovine	 serum	 and	passaged	2–4	times	before	use	in	experiments.	NIH-3T3	cells	were	obtained	from	ATCC	and	maintained	in	DMEM	with	10%	fetal	bovine	serum.	All	cells	were	cultured	with	10%	fetal	calf	serum	at	37	degrees	in	a	95%	air,	5%	CO2	humidified	incubator.	
Drug	library	screening	using	CCL5	and	CXCL10	expression	as	readout	The	COCTAIL	library	of	289	different	agents	was	plated	on	cultures	of	A549	cells	in	96	well	plates	 (10,000	cells/well)	using	 the	Biotek	robotic	 system.	24	h	 later,	2	different	concentrations	of	each	drug	were	added:	0.1	μM	and	1	μM.	TNFα	and	IFNγ	were	added	to	final	concentrations	of	0.2	ng/ml	and	1	ng/ml,	respectively.	All	conditions	were	in	duplicate,	and	 the	 average	 expression	 was	 used	 in	 Fig.	 2.3C.	 Cell	 supernatants	 were	 removed	 to	determine	amounts	of	secreted	chemokines	CCL5	and	CXCL10	24	hrs	later.	Cell	viability	was	also	 determined	 using	 the	 CellTiter-Glo®	 Reagent.	 Chemokine	 levels	 in	 the	 A549	supernatant	were	detected	using	Bead-Based	Multiplex	Assays	(Millipore	Inc.)	with	Luminex	technology.	
Mice		 All	mice	were	 bred	 and	housed	 in	 the	 animal	 facility	 at	 the	Moffitt	 Cancer	 Center	under	specific	pathogen-free	conditions.	129S4/SvJaeJ	mice	were	originally	obtained	from	the	Jackson	laboratory	and	were	used	for	LKR	tumor	studies.	Immunodeficient	SCID	mice	(CB17.Cg-PrkdcscidLystbg-J/Crl)	were	purchased	from	Charles	River	and	used	for	A549	tumor	growth	studies.	All	animal	experiments	were	approved	by	the	Institutional	Animal	Care	and	Use	Committee.	
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Flow	cytometric	analysis	Cells	 were	 incubated	 for	 5	 minutes	 at	 room	 temperature	 with	 Fc	 block	 (BD	Biosciences).	Staining	was	performed	in	1%	BSA/PBS	for	15	min	at	room	temperature	with	fluorochrome-conjugate	monoclonal	 antibodies,	 and	DAPI	was	 added	prior	 to	 analysis	 to	assess	 viability.	 Flow	 cytometric	 analysis	 was	 performed	 on	 an	 LSR	 II	 cytometer	 (BD	Biosciences).	Data	were	acquired	using	FACSDiva	software	(BD	Biosciences)	and	analyzed	using	FlowJo	software	(Tree	Star).	The	antibodies	used	from	Miltenyi	Biotec	were	CD120a	(TNF-R1)-APC,	human	(clone:	REA252);	CD120b	(TNFαRII)-PE,	human	(clone:	REA520).	PE	anti-mouse	CD120a	(TNFαR	Type	I/p55)	antibody	was	from	Biolegend.	
CRISPR/Cas9	gene	knockout	Human	 TNFR1CRISPR/Cas9	 knockout	 plasmids	 were	 purchased	 from	 Santa	 Cruz	Biotechnology.	 Specifically,	 cells	 were	 kept	 at	 40–80%	 confluency	 in	 a	 6-cm	 plate	 and	replaced	with	fresh	antibiotic-free	growth	medium	prior	to	transfection.	One	μg	of	plasmid	DNA	was	incubated	in	25ul	FuGENE	Transfection	Reagent	(Promega)	for	5	minutes	and	then	added	to	200ul	serum-free	opti-MEM	for	less	than	20	minutes.	After	72	hours	of	transfection,	green	fluorescent	protein-positive	(GFP+)	cells	were	single-cell	sorted	into	96-well	plates.	Single	clones	were	then	expanded	and	screened	by	flow	cytometry	and	western	blot	analysis	of	TNFR1	expression.	
Subcutaneous	tumor	studies	Cells	were	harvested	 in	the	 logarithmic	growth	phase	after	being	cultured	for	 less	than	2	weeks,	washed	once	in	injection	medium	(phenol-free	DMEM	supplemented	with	2%	FBS),	and	counted.	Cells	were	injected	subcutaneously	into	the	right	flank	of	mice	and	measured	every	4	days.	For	LKR	tumors,	106	LKR	cells	were	injected	in	phenol-free	DMEM	injection	
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medium.	 The	 tumor	 volume	 was	 determined	 as	 length	 x	 length	 x	 width/2.	 Trametinib	(1mg/kg	or	3mg/kg)	or	vehicle	was	oral	gavaged	daily;	αPD-1	(Clone	RMP1-14)	or	isotype	control	(Bio-X-Cell)	was	injected	intraperitoneally	(250	μg/mouse	per	injection).	To	deplete	T	cells,	300	μg/mouse	anti-mCD4	(Clone	GK1.5),	mCD8	(Clone	2.43),	or	isotype	control	(Bio-X-Cell)	were	injected	intraperitoneally	one	day	prior	to	anti-tumor	treatment	and	repeated	every	3	days	until	the	experiment	endpoint.	For	intratumoral	cytokine	injection,	100	μl	of	TNFα	and	IFNγ	(0.5	μg	each)	or	100	μl	PBS	were	injected	directly	into	the	tumor	tissue	for	3	consecutive	days	(day	11	to	day	13	post	tumor	cell	inoculation),	trametinib	dosing	was	from	day	10	 to	 day	14.	Mice	were	 sacrificed	 at	 the	 end	of	 the	 experiment	 or	when	 the	 tumor	volume	exceeded	2,000	mm3.	
Orthotopic	tumor	studies	and	bioluminescence	imaging		 2.5	 x105	 A549	 cells	 were	 injected	 with	 PBS	 plus	 1:1	 volume	 Matrigel	 (Corning)	percutaneously	 into	 the	 left	 lateral	 thorax	 in	mice	anesthetized	with	 isoflurane.	Fourteen	days	later,	trametinib	(1mg/kg)	or	vehicle	was	oral	gavaged	daily	for	14	days,	and	tumors	were	monitored	using	a	live	imaging	system.	At	the	end	of	the	study,	lungs	were	collected	for	histological	analysis.	For	bioluminescence	imaging	(BLI),	firefly	luciferase-expressing	A549	or	 LKR	were	 used.	 The	 IVIS	 Imaging	was	 used	 to	 capture	 bioluminescence	 following	 i.p.	injection	of	4	mg	luciferin	(Gold	Biotechnology).		
Real-time	PCR	RNA	from	cell	lines	was	isolated	using	the	RNeasy	kit	(QIAGEN).	Briefly,	500	ng	RNA	was	reverse	transcribed	to	cDNA	using	TaqMan	reverse-transcriptase	(Applied	Biosystems).	A	 SYBR	 Green	 Real-Time	 PCR	 Master	 Mixes	 kit	 (Life	 Technologies)	 was	 used	 for	 the	thermocycling	reaction	in	an	Applied	Biosystems	7900HT	Sequence	Detection	System.	All	
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samples	were	run	in	triplicate	and	were	normalized	to	mouse	rRNA	18s	or	human	GAPDH.	All	gene	expression	studies	were	repeated	in	independent	experiments.	Primer	sets:	Human	CXCL10		(Forward:	5’-GAAATTATTCCTGCAAGCCAATTT	-3’,		Reverse:	5’	-TCACCCTTCTTTATGTAGCA-3’)	Human	CCL5		(Forward:	5’-TCCTGCAGAGGATCAAGACA	-3’,	Reverse:	5’	-CAATGTAGGCAAAGCAGCAG	-3’)	Human	CCL2		(Forward:	5’-AGTGTCCCAAAGAAGCTGTG	-3’,	Reverse:	5’	-GATTCTTGGGTTGTGGAGTG	-3’)	Human	TNFAIP3		(Forward:	5’-CCTTGCTTTGAGTCAGGCTGT	-3’,		Reverse:	5’	-TAAGGAGAAGCACGAAACATCGA	-3’)	Human	TNF		(Forward:	5’-CTGCTGCACTTTGGAGTGAT-3’,		Reverse:	5’	-GGACCTGGGAGTAGATGAGG-3’)	Human	GAPDH		(Forward:	5’-ATCAAGAAGGTGGTGAAGCAG	-3’,		Reverse:	5’-TGTCGCTGTTGAAGTCAGAGG	-3’)	Primers	for	human	TNFRSF1A	and	TNFRSF1B	were	purchased	from	realtimeprimers.com.	
Drugs	Trametinib,	 dabrafenib,	 and	 AZD8330	 were	 purchased	 from	 Selleckchem,	binimetinib	was	 from	 Chemietek,	 and	 cobimetinib	was	 from	Active	 Biochem.	 Compound	
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concentrations	used	in	experiments	were	denoted	in	figures	and	figure	legends.	To	compare	the	TNFR1	upregulation	effects,	higher	end	doses	of	anti-cancer	agents	were	used:	50	μM	LY294002	213,	30	nM	romidepsin	20,	and	40	μM	214	cisplatin	were	used.	
Western	blot	analysis	and	Luminex	assay	Total	 cellular	 protein	 was	 extracted	 using	 Pierce	 RIPA	 Buffer	 (Thermo)	supplemented	 with	 1%	 proteinase	 inhibitors	 (Roche)	 and	 1%	 phosphatase	 inhibitors	(Sigma).	Nuclear	proteins	were	extracted	based	on	a	previous	protocol	215.	Cell	extracts	were	subjected	 to	sodium	dodecyl	sulfate–polyacrylamide	gel	electrophoresis	 (SDS-PAGE;	12%	polyacrylamide	gels);	and	then	transferred	to	PVDF	membranes	(Bio-Rad)	and	blocked	with	5%	 nonfat	 milk	 in	 TBS–Tween	 20	 (TBST).	 The	 membranes	 were	 then	 incubated	 with	primary	antibodies	overnight	at	4	°C.	After	3	washes	with	TBST,	membranes	were	probed	with	HRP-conjugated	secondary	antibody	for	1	hour	at	room	temperature	and	reacted	with	Western	 Lightning	 Plus	 ECL	 Substrate	 (Fisher).	 The	 antibodies	 used	 were	 (from	 Cell	Signaling)	 Phospho-p44/42	 MAPK	 (Erk1/2)	 (Thr202/Tyr204)	 (D13.14.4E),	 Phospho-p44/42	MAPK	(Erk1/2)	(Thr202/Tyr204)	(20G11),	p44/42	MAPK	(Erk1/2),	Phospho-	NF-κB	p65	(RelA)	(Ser536)	(93H1),	Cleaved	caspase	3	(Asp175),	and	Phospho-Stat1	(Tyr701)	(58D6)	Rabbit	mAb,	Stat1	Antibody.	In	addition,	antibodies	from	Santa	Cruz	Biotechnology	were	NF-κB	p65	(C-20X),	TNFR1	Antibody	(H-5),	and	β-actin	(C4).	Cell	culture	supernatants	were	 analyzed	 for	 CXCL10	 and	 CCL5	 by	 the	 Luminex	 assay	 (Millipore),	 following	 the	manufacturer’s	instructions.		
Retroviral	transduction	Retroviruses	were	prepared	by	transfecting	HEK	293T	cells	with	pBABE	expressing	KRAS-G12D,	pLPC,	pLPC-mTNFR1,	and	packaging	vectors.	Supernatant	containing	viruses	
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were	collected	2	days	after	transfection.	Cells	were	infected	by	centrifugation	for	60	min	in	the	presence	of	viral	supernatant	and	polybrene	(4	mg/ml).	Two	days	later,	transduced	cells	were	selected	for	puromycin	resistance.	
Cell	cycle,	proliferation	analysis,	and	synergy	calculations	104	or	3×104	cells	were	seeded	into	6-well	plates,	then	incubated	with	trametinib	(1	nM	or	10	nM)	(Selleckchem)	or	DMSO	with	or	without	recombinant	TNFα	and	IFNγ	(2	ng/ml	each)	(eBioscience)	for	up	to	4	days.	Drug	and	cytokines	were	replenished	on	day	2.	Cell	counting	was	conducted	on	days	2	and	4.	Drug	combination	effects	were	evaluated	using	the	Bliss	model	of	independence	216.	For	cell	cycle	analysis,	cells	were	collected	on	day	2,	washed	in	PBS,	and	fixed	with	70%	ethanol	overnight	at	4	°C.	Before	analysis,	cells	were	washed	in	PBS	and	incubated	with	propidium	iodide	(PI)	solution	with	RNase	A	(Abcam)	for	30	minutes	at	37	°C.	The	samples	were	then	used	for	FACS	analysis.	Acquisition	was	performed	using	the	FACSDiva	(BD);	raw	data	were	processed	and	analyzed	using	ModFit	LT	(Verity	Software	House).	 Percentage	 of	 cells	 in	 each	 cell	 cycle	 phase	 (G1,	 G2/S,	 M)	 was	 presented	 using	contingency	table	to	conduct	statistic	test.	
Tumor	histopathology	and	IHC	staining	Subcutaneous	tumors	or	lung	orthotopic	specimens	were	fixed	in	4%	PBS-buffered	formalin,	dehydrated	and	embedded	 in	paraffin,	 and	sectioned	and	processed	 for	hematoxylin	and	eosin	(H&E)	staining.	For	 immunohistochemistry	(IHC),	 the	sections	were	deparaffinized,	heated	 for	 antigen	 retrieval,	 and	 incubated	 with	 the	 primary	 antibody	 to	 pERK	(Thr202/Tyr204)	 (Cell	 signaling).	 The	 anti-rabbit	 secondary	 antibody	 (Ventana),	 in	combination	with	streptavidin/horseradish	peroxidase,	was	used	to	detect	the	signal.	Lastly,	the	sections	were	lightly	counterstained	using	hematoxylin.	All	staining	was	performed	at	
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the	Moffitt	 Cancer	 Center	 Tissue	 Core	 Facility	 using	 a	 Ventana	 Discovery	 XT	 automated	system.	Slides	were	validated	by	pathologists.	Images	were	scanned	and	analyzed	in	Aperio	eSlideManager	using	Aperio	ImageScope	software.	
Microarray	studies	Microarray	analysis	was	initiated	with	100	ng	of	total	cellular	RNA	from	each	cell	line.	RNA	was	converted	to	cDNA	and	then	amplified	and	labeled	with	biotin	using	the	Ambion	Message	Amp	Premier	RNA	Amplification	Kit	(Life	Technologies,	Grand	Island,	NY)	following	the	manufacturer’s	protocol.	The	labeled	RNA	was	hybridized	to	Affymetrix	U133	Plus	2.0	microarrays,	and	the	staining	and	scanning	of	the	chips	followed	the	prescribed	procedure	outlined	in	the	Affymetrix	technical	manual.	Results	were	analyzed	and	annotated	using	the	Bioconductor	 R	 packages:	 affy,	 gcrma,	 and	 hgu133plus2.db.	 All	 microarray	 data	 will	 be	deposited	in	a	public	database	upon	acceptance	of	this	manuscript.	Heatmaps:	Heatmaps	were	generated	by	calculating	the	Z-score	on	a	gene-level	basis	between	each	sample.	Clustering	was	done	using	the	scipy	Python	library	for	 linkage	and	distance	calculations	and	matplotlib	for	visualization.	Ward	linkage	and	Euclidean	distance	were	 used	 for	 clustering	 the	 samples.	 Z-score	was	 represented	 on	 a	 scale	 of	 3	 standard	deviations	from	the	mean	value.	
Patient	dataset	and	RNA-seq	data	analysis	De-identified	human	subject	RNA-seq	data	were	utilized	as	described	below	217.	Bam	files	with	reads	aligned	to	the	hg19	reference	genome	were	downloaded	from	the	European	Genome-phenome	Archive	(EGA	S00001000992)	using	the	EGA	download	client.	Expression	counts	were	summarized	at	the	gene	level	using	the	refseq	gene	model	using	htseq-count,	with	 the	 feature	 overlap	 resolution	 method	 set	 to	 "union".	 Read	 counts	 reported	 were	
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normalized	 to	 estimated	 library	 sizes	 using	 the	 R	 package	 DESeq2.	 Heatmaps	 were	generated	as	described	above.	NF-κB	signature:	Loading	coefficients	were	generated	through	principal	component	analysis	of	 the	10-gene	NF-κB	signature	171.	The	 first	principal	component	was	used.	The	signature	score	was	created	by	multiplying	the	Z-score	for	each	gene	for	each	sample	by	the	loading	coefficient	for	that	gene.	The	cumulative	sum	of	these	scores	was	taken	and	divided	by	the	number	of	genes	in	the	signature	to	generate	a	score	for	each	sample.	A	paired	t-test	was	performed	on	pre-	and	on-treatment	gene	expression	data	to	assess	the	impact	of	the	BRAFi/MEKi	 treatments	on	 the	NF-κB	pathway.	The	10-gene	NF-κB	 signature	was	GBP1,	
PSMB9,	IRF1,	TAP1,	TNFAIP3,	CCL5,	PSMB8,	IL32,	SH2B3,	and	NFKBIE.	
Statistical	analysis	For	two-group	comparisons,	a	Student’s	or	paired	t-test	(two-sided)	was	applied.	In	time-course	 experiments	 that	 involved	 repetitive	 measurements,	 two-way	 ANOVA	 was	applied	to	determine	group	differences.	Significance	for	multiple	condition	experiments	was	determined	 using	 one-way	 ANOVA.	 Sidak’s	 or	 Tukey’s	 method	 were	 used	 for	 type	 I	correction	in	multiple	comparisons.	For	in	vivo	experiments,	Dunnett’s	method	was	adopted	to	 compare	 each	 treatment	 group	 with	 the	 control	 group.	 Correlations	 between	 two	numerical	metrics	were	determined	using	Pearson’s	r.	A	chi-squared	test	with	Bonferroni	correction	was	applied	to	determine	the	significance	for	cell	cycle	data.	Differences	between	tumor	growth	curves	were	determined	by	 two-way	ANOVA.	 In	 the	 figures,	significance	 is	noted	using	*p	<	0.05,	**p	<	0.01,	***p	<	0.001,****p	<	0.0001,	ns,	not	significant.	All	data	shown	in	the	bar	graphs	are	the	mean	±	SD	of	at	least	three	biological	replicates.	Statistical	analysis	was	conducted	using	Prism7	(GraphPad)	software.	
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Results	
MEK	inhibitors	enhance	TNFα	induced	gene	expression		
			
Figure	 2.1	 MEK	 inhibitors	 enhance	 TNFα-induced	 gene	 expression	 in	 melanoma.	 (A)	 NF-κB	signature	activity	in	paired	melanoma	patient	biopsies	at	pre-treatment	(pre)	and	under	vemurafenib	or	dabrafenib	plus	trametinib	treatment	(on).	Individual	lines	represent	each	pair	of	biopsies,	anonymized	patient	ID	along	with	the	tumor	reduction	rate	(%).	(B)	Correlation	between	individual	patient	response	(%	 tumor	 reduction)	 to	 treatment	 and	 NF-κB	 signature	 score	 in	 on-treatment	 biopsies.	 Red	 line	represents	 Pearson’s	 linear	 correlation.	 (C–D)	Time	 course	 expression	 of	TNF	 and	TNFAIP3	mRNA	 in	WM164	and	1205Lu	as	indicated.	Cells	were	incubated	with	trametinib	(TRA,	10nM)	or	left	unstimulated	for	24	hours,	with	or	without	2	ng/ml	TNFα	added	for	indicated	time	periods.	0	h	on	the	x-axis	indicates	no	treatment	(black	circle)	or	TRA	alone	treatment	for	24	h	(red	circle).	Gene	expression	was	determined	in	 triplicate	 samples	 by	 qPCR	 and	 normalized	 to	 unstimulated	 cells.	 Two-way	 ANOVA	 was	 used	 to	determine	the	significance	of	difference	between	single	and	combined	treatments	(indicated	on	top).	A	
post	hoc	Sidak’s	multiple-comparison	test	for	each	time	point	was	also	performed	and	is	overlaid	on	the	plot	at	specific	time	points.	*p<0.05,	**p<0.01,	***p<0.001.	NS:	not	significant.			
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Figure	2.2	MEK	inhibitors	enhance	TNFα-induced	gene	expression	in	lung	cancer.	(A)	Microarray	expression	of	select	TNFα	target	genes	in	A549	subjected	to	indicated	treatments;	TRA	treatment	was	24	h,	TNFα	was	2	h.	Expression	value	is	represented	using	a	z-score	range	of	3	standard	deviations	from	the	mean.	(B)	Time	course	expression	of	TNF	and	TNFAIP3	mRNA	in	A549	as	described	in	Fig.	2.1C.	(C)	Time	course	expression	of	TNF	and	TNFAIP3	mRNA	in	H2122.	Assay	conditions	and	analysis	were	the	same	as	in	Fig.	2-1C.	(D)	Time	course	expression	of	CXCL10	in	A549;	cells	were	incubated	with	TRA	for	24	h	or	left	unstimulated,	with	or	without	2	ng/ml	cytokines	(TNFα,	IFNγ)	added	for	indicated	time	period.	Two-way	ANOVA	 was	 used	 to	 determine	 the	 significance	 of	 difference	 with	 and	 without	 presence	 of	 TRA	 in	indicated	groups.	Post	hoc	Sidak’s	multiple-comparison	test	was	performed	and	is	overlaid	on	the	plot	for	the	 TNFα	 +	 IFNγ	 and	 TNFα	 +	 IFNγ	 +	 TRA	 group	 comparison.	 *p<0.05,	 **p<0.01,	 ***p<0.001.	 NS:	 not	significant.	 	 (E)	A549	 supernatants	were	 collected	 from	A549	 cells	 subjected	 to	 indicated	 treatments,	CXCL10	secretion	was	determined	using	the	Luminex	assay.	Data	represent	the	mean	±	SD.	Significances	were	 determined	 using	 one-way	 ANOVA	 and	 a	 post	 hoc	 Sidak’s	 multiple-comparison	 test.	 *p<0.05,	**p<0.01,	***p<0.001.	NS:	not	significant.	
UT TRA TNFα
TRA
TNFα
0 h
0 .
5 h 2 h 6 h 2 4
h
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
T N F
c y to k in e  in c u b a t io n  t im e
R
el
at
iv
e 
A
m
o
u
n
t
T N F a
T R A + T N F a * * *
* * * *
* * * *
* * * *
* * *
0 h
0 .
5 h 2 h 6 h 2 4
h
0
2 0
4 0
6 0
8 0
T N F A IP 3
c y to k in e  in c u b a t io n  t im e
R
el
at
iv
e 
A
m
o
u
n
t
T N F a
T R A + T N F a * * * *
* * * *
* * * *
* * * *
* * * *
0 h
0 .
5 h 2 h 6 h 2 4
h
0
2 0
4 0
6 0
8 0
1 0 0
T N F
c y to k in e  in c u b a t io n  t im e
R
el
at
iv
e 
A
m
o
u
n
t
T N F a
T R A + T N F a * * * *
* * * *
* * * *
* * * *
* *
0 h
0 .
5 h 2 h 6 h 2 4
h
0
1 0
2 0
3 0
T N F A IP 3
c y to k in e  in c u b a t io n  t im e
R
el
at
iv
e 
A
m
o
u
n
t
T N F a
T R A + T N F a * * * *
* * * *
* * * *
* * * * * * * *
* * * *
U T
IF
N
g+
T N
F a
T R
A  
+  
IF
N
g+
T N
F a
0
5 0
1 0 0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
C X C L 1 0
p
g
/m
L
* *
0 h
0 .
5 h 2 h 6 h 2 4
h
0
5 0
1 0 0
2 0 0
4 0 0
6 0 0
8 0 0
C X C L 1 0
c y to k in e  in c u b a t io n  t im e
R
el
at
iv
e 
A
m
o
u
n
t
T N F a
IF N g
T N F a + IF N g
T R A + IF N g
T R A + T N F a
T R A + T N F a + IF N g
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
A B
C
D E
	46 
	 Inhibitors	of	BRAF	(BRAFi	e.g.	dabrafenib)	and	MEK	(e.g.	 trametinib)	prevent	ERK	activation	 and	 are	 the	 standard	 of	 care	 for	 treatment	 of	 BRAF	 mutant	 melanoma.	 To	determine	 whether	 BRAFi/MEKi	 impact	 NF-κB	 signaling,	 we	 used	 RNA-sequencing	 data	from	pre-	and	on-treatment	biopsies	of	patients	in	a	recent	study	217.	We	used	an	NF-κB	gene	expression	signature	171	to	determine	potential	changes	in	NF-κB	activity	after	BRAFi/MEKi	treatment.	Importantly,	NF-κB	pathway	activity	was	significantly	enhanced	after	treatment	
(Fig.	2.1A).	Further,	on-treatment	NF-κB	activity	was	significantly	associated	with	the	depth	of	patient	response	to	treatment	(Fig.	2.1B).	TNFα	is	a	master	activator	of	NF-κB,	including	in	the	tumor	microenvironment,	and	previous	studies	have	shown	increased	TNFα	levels	in	melanoma	patients	 undergoing	BRAFi	 treatment	 218-220.	We	hypothesized	 that	MEKi	may	increase	TNFα	expression	and/or	TNFα	induced	NF-κB	activation	leading	to	elevated	target	gene	expression.	We	tested	this	proposal	in	vitro	by	using	BRAF	mutant	WM164	and	1205Lu	human	melanoma	cell	lines	to	determine	changes	in	mRNA	expression	of	TNF	and	the	TNFα	target	gene	TNFAIP3	(aka	A20).	Consistent	with	previously	established	autocrine	regulation	of	TNFα,	we	found	that	TNFα	enhanced	expression	of	TNF	in	addition	to	TNFAIP3.	Notably,	the	MEKi	enhanced	TNFα-induced	expression	of	both	genes	in	these	melanoma	cell	lines	(Fig.	
2.1C,	D).	These	results	suggest	 that	MEKi	potentiate	TNFα	signaling	 in	melanoma	cells,	a	process	that	may	be	linked	to	enhancement	of	NF-κB	activity	after	BRAFi/MEKi	treatment.		In	contrast	to	melanoma,	MEKi	have	shown	limited	efficacy	in	lung	cancer	treatment	
61,203.	With	the	goal	of	defining	strategies	to	increase	vulnerability	of	lung	cancer	to	MEKi,	we	next	determined	whether	a	similar	potentiation	of	TNFα-induced	gene	expression	by	MEKi	was	 evident	 in	 lung	 cancer	 cells.	 To	 broadly	 assess	 such	 a	 role	 for	MEKi,	we	 performed	
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exome-wide	gene	expression	studies	in	the	KRAS	mutant	human	lung	adenocarcinoma	cell	line	A549.	Interestingly,	the	MEKi	slightly	enhanced	expression	of	several	TNFα	target	genes,	including	TNF	and	TNFAIP3,	but	the	highest	levels	of	expression	were	achieved	after		
Table	1.	MEK	inhibitors	enhance	TNFα-induced	gene	expression.		Sample	 Treatment	Time	 TNF	 TNFAIP3	 CCL2	 CCL5	 CXCL10	UT	 Untreated	 	 3.32	 8.66	 8.93	 5.49	 3.50	TNF_2h	 TNF	 2h	 6.94	 12.70	 13.26	 6.58	 5.73	TRA_24h	 TRA	 	 5.42	 10.19	 11.42	 8.23	 5.94	TRA_TNF_2h	 TRA+TNF	 2h	 9.71	 13.53	 14.19	 10.25	 6.31		Log2	expression	values	of	microarray	data	shown	in	Fig.	2.2A.		combined	MEKi	and	TNFα	treatment	(Fig.	2.2A	and	Table	1).	qRT-PCR	confirmed	the	ability	of	MEKi	to	enhance	expression	of	TNF	and	TNFAIP3	in	A549	alone	and	when	combined	with	TNFα	(Fig.	2.2B)	and	in	the	H2122	lung	cancer	cell	line	(Fig.	2.2C).	TNFα	and	IFNγ	synergize	in	 regulating	 the	 expression	 of	 a	 host	 of	 immune	 function	 genes,	 such	 as	 the	 chemokine	
CXCL10,	 which	was	 found	 to	 be	 upregulated	 by	 TNFα	 +	MEKi	 (Fig.	 2.2A).	 TNFα	 +	 IFNγ	synergistically	enhanced	CXCL10	expression,	which	was	further	enhanced	in	the	presence	of	MEKi	(Fig.	2.2D).	The	same	results	were	obtained	when	the	expression	 levels	of	CXCL10	protein	were	determined	(Fig.	2.2E).		
MEK	and	ERK	inhibitors	stimulate	TNFα	+	IFNγ-induced	chemokine	expression	
	 We	next	 determined	whether	MEKi	 stimulation	 of	 TNFα-induced	 gene	 expression	also	occurred	in	response	to	other	anti-cancer	agents.	We	assembled	an	in-house	customized	library	of	289	targeted	compounds	that	covers	all	major	target	classes,	such	as	epigenetic	
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enzymes,	hedgehog,	HSP90,	and	Notch,	but	has	a	stronger	focus	on	protein	and	lipid	kinases	that	reflects	the	current	landscape	of	targeted	agents	in	clinical	use	and	development	221.			
	
Figure	2.3.	MEK	and	ERK	inhibitors	stimulate	TNFα	+	IFNγ-induced	chemokine	expression.	
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(A)	 Composition	 of	Moffitt’s	 customized	 COCTAIL	 library	 of	 289	 targeted	 drugs/drug	 candidates.	 (B)	Outline	of	drug	screening	assay	used	to	identify	agents	that	enhance	TNFα	+	IFNγ-induced	expression	of	CXCL10	and/or	CCL5	2-fold	over	cytokines	alone.	TNFα	and	IFNγ	were	added	to	final	concentrations	of	0.2	ng/ml	and	1	ng/ml,	respectively.	Library	compounds	were	used	at	0.1	μM	or	1	μM.	(C)	Agents	that	enhance	TNFα-	and	IFNγ-induced	expression	of	CXCL10	and/or	CCL5	2-fold	over	cytokines	alone	in	at	least	one	of	the	four	tested	conditions	are	indicated.	Drug	target	categories	are	also	indicated	(see	results	for	details).	Arry162	(aka	MEK162,	binimetinib),	a	MEKi,	induced	a	1.9-fold	increase	and	was	also	added	to	show	similarity	to	other	MEKi	and	is	indicated	with	an	*.		Certain	drugs	were	used	in	duplicate	(LC-161;	shown	as	1	and	2)	to	test	the	reproducibility	of	results.			This	library	consists	of	more	than	70%	of	compounds	that	are	either	FDA	approved	or	in	clinical	development	(hence,	the	name	COCTAIL—Collection	of	Clinical	Targeted	Agents	In	Lung	 cancer)	 (Fig.	 2.3A).	 In	 addition,	 we	 incorporated	 target	 redundancy	 so	 that	 most	targets	 were	 covered	 by	 several	 compounds.	 Both	 CXCL10	 and	 CCL5	 are	 synergistically	regulated	 by	 TNFα	 +	 IFNγ.	 We	 used	 this	 library	 to	 identify	 anti-cancer	 agents	 that	 can	enhance	 TNFα	 +	 IFNγ-induced	 expression	 of	 CXCL10	 and	 CCL5	 in	 A549	 cells.	 The	combination	 of	 TNFα	 +	 IFNγ	 was	 used	 based	 on	 the	 reasoning	 that	 agents	 capable	 of	enhancing	the	already	high	expression	induced	by	these	cytokines	will	yield	the	most	robust	hits.	Using	the	basic	scheme	outlined	in	Fig.	2.3B,	we	determined	the	ability	of	two	different	concentrations	 (0.1	 and	 1	 μM)	 of	 each	 of	 these	 agents	 to	 increase	TNFα	 +	 IFNγ-induced	secretion	of	CXCL10	and	CCL5.	Using	a	2-fold	cut-off	for	the	ability	to	increase	expression	in	one	of	the	4	tested	conditions	over	TNFα	+	IFNγ	alone,	16	agents	were	identified	as	potential	hits.	 Remarkably,	 13	 of	 these	 agents	 were	 either	 MEK	 (including	 trametinib)	 or	 ERK	inhibitors	(Fig.	2.3C).	The	additional	agents	included	2	SMAC	mimetics,	which	target	cIAP	proteins	and	activate	TNFα	signaling	222,	and	a	phosphodiesterase	inhibitor	(Fig.	2.3C).	We	concluded	 that	 the	 MEK/ERK	 inhibitors	 can	 function	 to	 enhance	 TNFα	 +	 IFNγ-induced	signaling	responses.	Furthermore,	the	multitude	of	MEK/ERK	inhibitors	identified	suggests	
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that	the	on-target	effects	of	these	drugs	are	responsible	for	the	enhancement	of	TNFα	+	IFNγ-induced	responses.		
Figure	2.4.	MEKi	enhance	TNFα	target	gene	expression	and	NF-κB	activity.	
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(A)	Cell	surface	TNF	receptor	1	(TNFR1)	expression	in	A549	was	examined	by	flow	cytometry	after	24	h	trametinib	 (TRA)	 treatment	at	1	nM,	10	nM,	and	100	nM.	US,	unstained;	UT,	untreated.	 (B)	A549	cell	surface	expression	of	TNFR1	and	TNFR2	was	quantified	based	on	median	fluorescence	intensity	(MFI).	(C)	Total	cell	 lysates	were	prepared	to	perform	western	blots	to	detect	ERK	and	TNFR1	in	A549	after	indicated	treatments.	(D)	Expression	of	cell	surface	TNFR1	in	A549	was	determined	after	incubation	with	drugs	 targeting	MEK	 (trametinib	 100	 nM),	 PI3K	 (LY294002	 50	 μM),	 HDAC	 (romidepsin	 30	 nM),	 and	cisplatin(40	 μM)	 for	 24	 h.	 (E)	Western	 Blot	 showing	 RelA	 phosphorylation	 (serine	 536;	 p-RelA)	 and	overall	nuclear	levels	of	RelA	(p65)	in	A549	that	were	incubated	with	TNFα	or	100	nM	trametinib	(TRA)	for	 indicated	 time	periods	or	 left	untreated.	 (F)	Expression	of	TNF	 and	TNFAIP3	mRNA	 in	A549	after	treatment	of	100	nM	TRA	for	indicated	periods.	Significance	was	determined	using	Dunnett's	multiple	comparisons.	(G)	Western	blot	showing	RelA	phosphorylation	(serine	536;	p-RelA)	and	overall	nuclear	levels	of	RelA	(p65)	in	A549	that	were	subjected	to	indicated	treatments,	total	incubation	time	of	TRA	was	24	h,	and	cytokines	were	added	in	the	last	6	h.	Concentrations:	TRA	100	nM,	IFNγ	50	ng/ml,	TNFα	25	ng/ml.	ERK	and	β-actin	levels	are	also	shown.			
MEKi	enhance	cell	surface	expression	of	TNFα	receptor	1	To	 investigate	 how	 TNFα	 and	 TNFα	 +	 IFNγ	 gene	 expression	 responses	 might	 be	enhanced	 by	 MEKi,	 we	 next	 determined	 its	 impact	 on	 the	 expression	 of	 the	 two	 TNFα	receptors:	TNFR1	and	TNFR2.	Interestingly,	MEKi	led	to	dramatic	cell	surface	upregulation	of	TNFR1,	but	not	TNFR2,	in	a	dose-dependent	manner	in	A549	(Fig.	2.4A–B).	However,	the	total	 levels	 of	 TNFR1	 were	 not	 impacted	 (Fig.	 2.4C),	 suggesting	 that	 MEKi	 increase	membrane	localization	of	TNFR1.	TNFα	treatment	itself	did	not	enhance	TNFR1	cell	surface	expression	(Fig.	2.4A,	B).	In	contrast	to	MEKi,	cytotoxic	agents	and	drugs	targeting	PI3K	or	HDACs	failed	to	upregulate	TNFR1	cell	surface	expression	(Fig.	2.4D).	We	next	determined	whether	MEKi	induced	an	increase	in	TNFR1-impacted	NF-κB	activation	by	TNFα	and	IFNγ	as	determined	by	RelA	phosphorylation	and	increased	nuclear	translocation	of	RelA.	MEKi	alone	activated	NF-κB	and	its	target	genes	TNF	and	TNFAIP3	in	A549	(Fig.	2.4E-F),	but	in	combination	 with	 TNFα,	 NF-κB	 activation	 was	 synergistically	 enhanced	 (Fig.	 2.4G).	Interestingly,	the	combination	of	MEKi	+	IFNγ	also	enhanced	NF-κB	activation,	suggesting	that	 MEKi	 enhancement	 of	 TNFR1	 expression	may	 also	 potentiate	 IFNγ	 responses	 (Fig.	
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2.4G).	Finally,	the	highest	activation	of	NF-κB	was	seen	in	the	presence	of	MEKi	and	both	cytokines.		
		
Figure	 2.5.	 MEKi	 enhance	 cell	 surface	 expression	 of	 TNFα	 receptor	 1.	 (A)	 Cell	 surface	 TNFR1	expression	fold	change	in	indicated	cell	lines	upon	24	h	100	nM	TRA	treatment.	Plot	represents	mean	±	SD	of	3	replicates.	Sidak’s	correction	for	multiple	t-test	was	applied	to	determine	the	significance	of	the	change	in	each	cell	line.	(B)	Expression	of	cell	surface	TNFR1	in	BRAF	mutant	melanoma	lines	(Wm164	and	1205Lu)	was	determined	by	flow	cytometry	after	incubation	with	indicated	inhibitors	for	24	h.	US,	unstained;	UT,	untreated;	DAB,	dabrafenib	5	μM;	TRA:	trametinib	100	nM.			 MEKi	also	increased	TNFR1	surface	expression	in	multiple	additional	human	lung	cell	lines	 such	 as	 H2122,	 H1437,	 HCC44,	 and	 PC9	 (Fig.	 2.5A).	 In	 the	 BRAF	 mutant	 human	melanoma	cell	lines	WM164	and	1205Lu,	cell	surface	TNFR1	was	induced	by	both	MEKi	and	BRAFi	(Fig.	2.5B).	TNFR1	upregulation	was	seen	in	both	KRAS	mutant	(A549,	H2122,	HCC44,	H2009)	and	wild-type	(H1437,	PC9)	human	lung	cancer	cell	lines	(Fig.	2.5A).	We	believe	this	
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likely	 reflects	 the	 common	utilization	of	MEK-ERK	signaling	by	 cancer	 cells	 regardless	of	oncogene	mutation.	 Similar	 results	were	 also	obtained	 in	mouse	 lung	 cancer	LKR,	which	harbors	 the	Kras	mutation	(Fig.	2.5A).	We	next	 tested	3	additional	MEKi	 included	 in	 the	above	 screening	 (cobimetinib,	 binimetinib/MEK162,	 and	 AZD8330)	 for	 their	 ability	 to	inhibit	pERK,	upregulate	TNFR1	expression,	and	induce	gene	expression	(Fig.	2.6A–C).	In	a	dose-dependent	manner,	these	MEKi	inhibited	pERK	and	upregulated	cell	surface	TNFR1	but	not	 TNFR2	 expression	 (Fig.	 2.6A–B).	Moreover,	 as	 observed	 in	Fig.	 2.4C	 for	 trametinib,	these	MEKi	did	not	impact	total	TNFR1	levels	(Fig.	2.6A).	Importantly,	we	found	a	strong	association	 between	 pERK	 inhibition	 and	 surface	 expression	 of	 TNFR1	 and	 target	 gene	expression	(Fig.	2.6D–F).	As	seen	with	trametinib,	these	MEKi	also	enhanced	TNFα-induced	
TNF	expression	in	a	dose-dependent	manner	(Fig.	2.6C).		Furthermore,	TNF	expression	strongly	correlated	with	pERK	inhibition	(Fig.	2.6E)	and	 expression	 of	 TNFR1	 (Fig.	 2.6F).	 We	 determined	 whether	 enhanced	 activation	 of	MEK/ERK	could	conversely	 reduce	TNFR1	expression.	 Importantly,	ectopic	expression	of	mutant	 KRAS	 in	 NIH-3T3	 fibroblasts	 enhanced	 ERK	 activation	 and	 reduced	 cell	 surface	TNFR1	 expression	 (Fig.	 2.6G,	 H).	 These	 results	 indicate	 the	 ability	 of	 MEKi	 to	 enhance	surface	expression	of	TNFR1,	which	in	turn	may	be	responsible	for	enhancement	of	TNFα-induced	gene	expression	responses.		To	determine	 the	 role	 in	MEKi-induced	 stimulation	of	 gene	 expression	 responses,	TNFR1	was	knocked-out	(KO)	in	A549	using	CRISPR/Cas9	technology.	TNFR1	absence	was	confirmed	by	flow	cytometry	and	western	blotting	(Fig.	2.7A,	B),	consistent	with	that	TNFα-induced	gene	expression	was	diminished	in	TNFR1	KO	A549	(Fig.	2.7C).	To	determine	the		
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Figure	2.6.	MEKi	enhance	cell	surface	expression	of	TNFα	receptor	1	in	a	dose-dependent	manner.		
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(A)	A549	cell	lysates	were	prepared	to	perform	western	blots	to	detect	p-ERK	and	TNFR1	after	treatments	with	indicated	MEK	inhibitors;	the	incubation	time	was	24	h.	TRA	(trametinib),	Cobi	(Cobimetinib),	Bini	(binimetinib/MEK162),	 and	AZD8330.	 (B)	 Cell	 surface	 TNFR1	 and	 TNFR2	 from	 experiment	 in	 A	was	determined	using	 flow	cytometry	using	 indicated	concentrations	of	MEKi.	 (C)	Expression	of	TNF	 from	experiment	 in	 A	 was	 determined	 using	 qPCR.	 One-way	 ANOVA	 and	 a	 post	 hoc	 Dunnett’s	 multiple-comparison	test	for	the	difference	between	TNFα	alone	and	the	combination	treatments	were	performed	and	indicated.	*p<0.05,	**p<0.01,	***p<0.001.	****p<0.0001.	(D-F)	Pearson’s	correlations	between	p-ERK	inhibition	potency	and	cell	surface	TNFR1	(D)	and	TNF	expression	(E)	and	TNFR1	surface	expression	and	
TNF	mRNA	expression	(F)	in	A549.	Data	points	were	from	results	in	A–C;	values	of	p-ERK	intensity	were	based	on	western	blot	densitometry	measurement.	(G)	Kras-G12D	was	expressed	in	NIH-3T3	cells	using	pBABE-Kras	retrovirus.	Western	blots	showing	ERK	and	b-actin	in	NIH-3T3	cells.	(H)	Cell	surface	TNFR1	expression	after	indicated	treatments	was	determined	in	NIH-3T3	cells	described	in	G.	Plot	represents	mean	±	SD	of	3	replicates,	Sidak’s	multiple-comparison	for	t-test	were	applied	to	determine	significance	of	the	changes.	****p<0.0001.				impact	of	TNFR1	absence	on	TNFα	and	IFNγ	gene	expression	responses,	we	assessed	the	level	of	CXCL10	because	it	is	dually	regulated	by	both	cytokines	(Fig.	2.2D).	The	absence	of	TNFR1	significantly	reduced	IFNγ	and	MEKi	+	IFNγ	induced	CXCL10	expression,	which	was	rescued	by	TNFR1	re-expression	(Fig.	2.7D).	Thus,	TNFR1	mediates	responses	 to	 IFNγ	+	MEKi	likely	through	MEKi	upregulation	of	TNFα-TNFR1	autocrine	signaling	that	synergized	with	IFNγ.	TNFα	alone	did	not	appreciably	induce	CXCL10,	but	a	notable	increase	was	seen	when	 TNFα	 was	 combined	 with	 MEKi.	 TNFα	 +	 IFNγ	 induced	 a	 high	 level	 of	 CXCL10	expression,	which	was	further	enhanced	by	MEKi	in	a	TNFR1-dependent	manner	(Fig.	2.7D).	These	 results	 suggest	 that	upregulation	of	TNFR1	by	MEKi	plays	a	key	 role	 in	enhancing	TNFα	and	IFNγ	target	gene	expression.		To	test	whether	MEKi	may	also	directly	impact	the	IFNγ	pathway,	we	determined	cell	surface	 IFNγ	 receptor	 1	 and	 2	 expression,	 which	 together	 make	 the	 IFNγ	 receptor	 a	heterodimer,	as	well	as	IFNγ-induced	STAT1	phosphorylation	in	the	presence	of	MEKi	(Fig.	
2.7E–H).	In	contrast	to	TNFR1,	we	did	not	observe	an	increase	in	either	IFNγ	receptor	chain	expression	(Fig.	2.7E).	Furthermore,	MEKi	did	not	impact	levels	of	IFNγ-induced	pSTAT1		
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Figure	2.7.	MEKi	enhance	TNFα	target	gene	expression.	
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(A)	Flow	cytometry	showing	cell	surface	TNFR1	expression	in	parental	and	TNFR1	knockout	(TNFR1KO)	A549	cells.	US,	unstained;	UT,	untreated.	TRA	treatment	was	at	100	nM.	(B)	Western	blot	showing	total	expression	of	TNFR1	in	A549	(parental),	untargeted,	and	TNFR1	knockout	(TNFR1KO)	cells.	(C)	A549	and	TNFR1	knockout	(TNFR1KO)	A549	were	stimulated	by	50	ng/ml	TNFα	for	6	h	or	left	untreated.	CCL2	and	
CCL5	mRNA	expression	was	normalized	to	untreated	cells.	(D)	TNFR1	expression	in	A549	was	knocked	out	 (TNFR1KO)	 using	 CRISPR/Cas9	 technology.	 To	 re-express	 TNFR1	 in	 TNFR1KO	 A549,	 cells	 were	infected	by	pLPC-TNFR1	or	pLPC	retrovirus.	CXCL10	mRNA	expression	was	determined	by	qPCR	after	indicated	treatments;	gene	expression	levels	were	normalized	to	unstimulated	cells.	Concentrations:	TRA	100	nM,	 IFNγ	50	ng/ml,	TNFα	25	ng/ml.	Data	 represent	 the	mean	±	SD	of	 triplicate	values.	Two-way	ANOVA	and	a	post	hoc	Tukey’s	multiple-comparison	test	was	performed	for	the	TNFα	+	IFNγ	and	TNFα	+	IFNγ	+	TRA	group	comparison,	as	indicated.	*p<0.05,	**p<0.01,	***p<0.001.	NS:	not	significant.	(E)	Cell	surface	IFNγ	receptor	1	and	receptor	2	expression	in	A549	was	determined	by	flow	cytometry	after	24	h	trametinib	(TRA)	or	1	h	IFNγ	10	ng/ml	treatment.	US,	unstained;	UT,	untreated.	(F)	In	total	lysates	of	A549,	STAT1	 phosphorylation	 levels	 were	 determined	 by	 western	 blotting	 after	 treatment	 with	 indicated	concentrations	 of	 IFNγ.	 TRA	 treatment	 was	 at	 100	 nM.	 (G)	 Same	 as	 in	 F,	 except	 two	 indicated	concentrations	of	IFNγ	were	used	and	stimulation	was	for	 indicated	time	periods	shown	in	hours.	(H)	A549	CXCL10	 expression	 after	 indicated	 treatments	 as	 in	G.	 Two-way	ANOVA	and	 a	post	 hoc	Tukey’s	multiple-comparison	were	used	to	determine	significance.				across	 several	 IFNγ	 concentrations	 (Fig.	 2.7F).	 At	 0.5	 and	 5	 ng/ml	 IFNγ	 treatment	 at	different	time	points,	MEKi	did	not	increase	pSTAT1	levels	but	substantially	increased	IFNγ-induced	CXCL10	expression	(Fig.	2.7G–H).	We	conclude	that	upregulation	of	both	TNFα-	and	IFNγ-induced	gene	expression	in	A549	is	mediated	by	MEKi-induced	increase	in	cell	surface	TNFR1.	
TNFα	and	IFNγ	modulate	MEKi-induced	growth	suppression	and	cell	death	In	addition	to	gene	expression	functions,	TNFα	is	known	as	a	potent	inducer	of	cell	death.	Furthermore,	TNFα	and	IFNγ	synergize	in	induction	of	cell	death	and	cell	cycle	arrest	
190,191.	We	next	tested	the	possibility	that	the	MEKi-induced	increase	in	TNFR1	expression	may	also	impact	cell	death	and	cell	cycle	arrest	responses.	Importantly,	we	observed	that	the	growth-suppressive	effects	of	MEKi	were	partly	attenuated	in	TNFR1	KO	A549,	but	the	re-expression	of	TNFR1	 in	 these	 cells	 re-sensitized	 them	 to	MEKi	(Fig.	2.8A).	These	 results	suggest	 that	 the	 activation	 of	 autocrine	 TNFR1/TNFα	 signaling	 by	 MEKi	 could	 enhance	growth	suppression.	We	next	 tested	the	 impact	of	exogenous	addition	of	TNFα	and	IFNγ.	
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TNFα	 alone	 and	 TNFα	 +	 IFNγ	 were	 found	 to	 reduce	 viable	 cell	 numbers	 modestly.	 As	expected,	MEKi	reduced	cell	numbers;	however,	the	combination	of	MEKi	with	TNFα	+	IFNγ	resulted	in	the	highest	reduction	in	viable	cell	numbers	(Fig.	2.8B).	Treatment	with	MEKi	in	the	presence	of	both	cytokines	 led	to	the	 largest	percentage	of	G1-phase	cells,	 the	 lowest	percentage	 of	 S-phase	 cells	 (Fig.	 2.8C),	 and	 the	 highest	 activation	 of	 apoptosis	 marker	cleaved	caspase	3	(Fig.	2.8D).	These	results	suggest	that	reduction	in	viable	cell	numbers	after	MEKi	and	cytokine	treatment	are	mediated	through	both	cell	cycle	arrest	and	cell	death	induction	(also	see	sections	below).			
	
Figure	2.8.	TNFα	and	IFNγ	enhance	MEKi-induced	growth	suppression	and	cell	death.	
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(A)	 In	vitro	MEKi	 sensitivity	of	A549.	TNFR1	was	 re-expressed	 in	TNFR1KO-A549	using	pLPC-TNFR1	retrovirus	 (TNFR1KO-TNFR1);	 pLPC	 was	 used	 as	 control	 (TNFR1KO-pLPC).	 104	 of	 A549,	 TNFR1KO,	TNFR1KO-TNFR1,	and	TNFR1KO-pLPC	were	seeded	into	6-well	plates	and	incubated	with	1	nM	TRA	or	left	 untreated	 for	 the	 next	 4	 days;	 viable	 cell	 numbers	were	 counted	 at	 day	 4	 for	 each	 cell	 line	 and	normalized	to	untreated.	(B)	Impact	of	TRA	and	cytokines	on	A549	growth	in	vitro.	3	X	104	cells	were	seeded	into	6-well	plates	and	incubated	with	10	nM	TRA	with	or	without	2	ng/ml	each	cytokine	(TNFα,	IFNγ)	for	the	next	4	days;	viable	cell	numbers	were	counted	on	day	4	and	normalized	to	untreated	(UT).	Plot	represents	mean	±	SD	of	3	replicates;	significance	was	determined	using	one-way	ANOVA	and	a	post	
hoc	Tukey’s	multiple-comparison	test	and	is	shown	for	indicated	comparisons.	****p	<	0.0001.	(C)	Cell	cycle	analysis	of	A549	after	treatments	indicated,	cells	were	collected	at	day	2	after	treatments.	Propidium	iodide	(PI)	staining	was	used	to	determine	the	percentage	of	cells	in	different	cell	cycle	stages	as	indicated.	Comparisons	were	made	using	a	chi-squared	test	with	Bonferroni	correction.	Plot	shows	representative	result	from	3	independent	experiments.	(D)	Western	blot	showing	apoptosis	marker	cleaved	caspase	3	expression	in	A549	after	48	h	of	indicated	treatment.	Cytokine	concentration	was	2	ng/ml.			 Utilizing	TNFR1	KO	A549,	we	next	tested	the	in	vivo	role	of	TNFR1	signaling	in	MEKi	anti-tumor	 response	 in	 an	 orthotopic	 lung	 tumor	 model	 using	 immunodeficient	 SCID	(Prkdcscid)	and	beige	(Lystbg)	mice.	In	contrast	to	vehicle-treated	mice,	dosing	of	mice	with	1	mg/kg	trametinib	was	associated	with	minimal	tumor	burden	(Fig.	2.9A,	B).	Contrastingly,	no	reduction	in	tumor	burden	was	noticed	after	MEKi	treatment	in	mice	bearing	TNFR1	KO	tumors	 (Fig.	 2.9A,	B).	 Importantly,	 pERK	was	 strongly	 inhibited	 by	MEKi	 in	KO	 tumors,	suggesting	 that	 trametinib	 retains	MEK	 targeting	 ability	 in	 these	 tumors	 (Fig.	 2.9C).	 To	longitudinally	 assess	 the	 impact	 of	MEKi	 on	 tumor	 growth,	 we	 utilized	 bioluminescence	imaging	(BLI)	in	parental	and	TNFR1	KO	A549.	Whereas	WT	tumor	growth	was	inhibited,	TNFR1	KO	tumors	continued	to	grow	after	MEKi	treatment	(Fig.	2.9D,	E).	Together	with	the	in	vitro	findings,	these	results	indicate	a	key	role	for	TNFR1	signaling	in	the	MEKi	anti-tumor	response.	 Furthermore,	 because	mouse	 TNFα	 cannot	 activate	 human	 TNFR1	 signals,	 the	anti-tumor	effects	of	MEKi	are	likely	mediated	by	stimulation	of	autocrine	TNFα	signaling.			
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Figure	2.9	In	vivo	role	of	TNFR1	signaling	in	MEKi	anti-tumor	response.	
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(A)	Trametinib	(TRA)	effect	on	growth	of	lung	orthotopic	A549	tumors	(WT)	and	TNFR1KO	A549	tumors	in	 immunodeficient	 SCID	mice.	 After	 14	 days	 of	 tumor	 cell	 inoculation,	 1	mg/kg	 TRA	 or	 vehicle	was	administered	 daily	 through	 oral	 gavage	 for	 14	 days.	 UT	 indicates	 vehicle-treated	mice.	 At	 the	 end	 of	treatment,	 lungs	were	 collected	 from	viable	mice	 for	H&E	 staining.	Tumor	percentage	was	quantified	based	 on	 tumor	 tissue	 area	 compared	 to	 total	 lung	 area	 (%).	 (B)	 H&E	 staining	 of	 paraffin	 sections	described	in	A.	(C)	p-ERK	IHC	staining	in	TNFR1KO	A549	tumors	(untreated	and	1	mg/kg	TRA	treated)	from	A.	(D–E)	Trametinib	(TRA)	effect	on	growth	of	lung	orthotopic	A549	tumors	(WT)	and	TNFR1KO	A549	 tumors	 in	 SCID	 mice.	 (D)	 Longitudinal	 monitoring	 of	 mice	 using	 bioluminescence	 intensities	normalized	to	the	same	scale,	individual	mouse	images	are	shown.	(E)	Total	flux	of	photons	of	individual	mice	was	calculated	and	normalized	to	the	value	at	the	beginning	of	treatment	(day	0).			
	
Figure	2.10	TNFα	and	IFNγ	synergize	with	MEKi	to	induce	lung	cancer	cell	death.	(A)	Impact	of	TRA	and	cytokines	on	LKR	growth	in	vitro	was	determined	as	in	Fig.	2.8C,	except	treatment	was	for	2	days.	Plot	represents	mean	±	SD	of	3	replicates;	significance	was	determined	using	one-way	ANOVA	and	a	post	
hoc	Tukey’s	multiple-comparison	test	and	is	shown	for	indicated	comparisons.	**	p<0.01,	***	p<0.001	****,	p	 <	 0.0001	 (B)	 Cell	 cycle	 analysis	 of	 LKR	 after	 treatments	 indicated	 was	 performed	 as	 in	 Fig.4C.	Comparisons	 were	 made	 using	 a	 chi-squared	 test	 with	 Bonferroni	 correction	 of	 S	 versus	 G1/G2	frequencies.	Plot	shows	representative	result	from	3	independent	experiments	(C)	Western	blot	showing	apoptosis	marker	cleaved	caspase	3(CC3)	in	LKR	cells	after	48	h	of	indicated	treatments.	(D)	Western	blot	showing	cleaved	caspase	3(CC3)	p19	and	p17	fragments	in	LKR	cells	in	response	to	indicated	cytokines	(numbers	 show	 individual	 cytokine	 concentrations)	 and	 trametinib	 after	 48	 h	 treatments.	 Viable	 cell	number	was	also	determined	and	is	indicated.			
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We	next	 tested	 the	 impact	 of	 TNFα	 and	 IFNγ	on	MEKi	 growth	 suppression	 in	 the	mouse	lung	cancer	LKR	cell	 line,	which	also	underwent	an	increase	in	TNFR1	cell	surface	expression	after	MEKi	treatment	(Fig.	2.5A).	As	in	A549	cells,	the	combination	of	MEKi	with	both	TNFα	and	IFNγ	led	to	the	strongest	reduction	in	cell	numbers	in	LKR	cells	(Fig.	2.10A).	However,	individual	cytokine	treatment	with	IFNγ	+MEKi	decreased	cell	numbers,	whereas	TNFα	+	MEKi	treatment	increased	cell	numbers	compared	to	MEKi	alone	(Fig.	2.10A).	To	better	understand	these	findings,	we	next	proceeded	to	define	the	individual	and	combined	roles	of	TNFα	and	IFNγ	in	LKR	cell	cycle	and	cell	death	regulation.	However,	TNFα	+	MEKi	or	TNFα	+	IFNγ	+	MEKi	did	not	appreciably	impact	S-phase	cells	compared	to	MEKi	alone	(Fig.	
2.10B).	This	was	distinct	from	the	above	results	with	A549	and	suggests	that	a	decrease	in	LKR	numbers	after	TNFα	+	IFNγ	+	MEKi	(Fig.	2.10A)	could	be	mediated	by	enhanced	cell	death.		To	assess	the	role	of	apoptosis	in	the	reduction	of	viable	cells	after	cytokine	and	MEKi	treatments,	we	determined	 the	 levels	of	 cleaved	caspase	3	 (CC3).	CC3	comprises	a	19-kd	(p19)	and	a	17-kd	(p17)	fully	activated	form,	both	of	which	were	detected	in	LKR	cells.	We	found	that	in	a	dose-dependent	manner,	TNFα	promotes	the	formation	of	the	p19	fragment	and	a	small	amount	of	p17	(Fig.	2.10C).	This	increase	was	not	evident	after	either	MEKi	or	IFNγ	treatment	(Fig.	2.10C).	Whereas	the	combination	of	TNFα	or	IFNγ	with	MEKi	led	to	distinct	and	complex	patterns	of	p19	and	p17	activation,	the	combination	of	all	3	agents	led	to	the	highest	level	of	p17	activation	(Fig.	2.10C).	To	determine	the	degree	of	enhancement	of	CC3	after	the	combination	treatment,	we	treated	LKR	cells	with	10	nM	MEKi	and	a	range	of	cytokine	concentrations	(2,	10,	and	50	ng/ml).	CC3	p17	generation	was	detected	at	the	higher	cytokine	concentrations	(10	and	50	ng/ml),	consistent	with	a	reduction	in	viable	cell	
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numbers	 (Fig.	2.10D).	However,	 CC3	p17	generation	was	dramatically	 enhanced	at	 all	 3	cytokine	concentrations	in	the	presence	of	MEKi	(Fig.	2.10D),	indicating	that	MEKi	enhances	sensitivity	to	cytokine-induced	apoptosis.	Collectively,	these	results	suggest	that	cell	death	induction	rather	than	cell	cycle	arrest	is	the	primary	mechanism	of	cell	number	reduction	in	LKR	cells	after	cytokine	and	MEKi	treatment.	We	next	determined	whether	the	cytokine	+	MEKi	effect	on	cell	viability	seen	in	vitro	was	also	evident	in	vivo.	A	tumor	stasis	effect	of	MEKi	was	observed	in	sub-cutaneous	(s.c.)	LKR	tumors	at	1	and	3	mg/kg	daily	dosing	in	an	LKR	(Fig.	2.11A).	Owing	to	the	similarity	of	response	at	these	two	concentrations,	further	studies	were	performed	at	the	1	mg/kg	dose.	Consistent	with	in	vitro	results,	upregulation	of	TNFR1	expression	in	tumor	cells	was	also	observed	 after	 MEKi	 treatment	 (Fig.	 2.11B).	 We	 then	 determined	 whether	 direct	intratumoral	injection	of	cytokines	could	impact	the	MEKi	anti-tumor	effect.	BLI	imaging	of	LKR	tumors	was	used	to	determine	the	treatment	impact	on	tumor	cell	viability.	Due	to	the	fact	that	TNFα	+	IFNγ	has	the	potential	to	make	tumor	cells	more	susceptible	to	T	cell	killing	(e.g.	by	upregulation	of	MHC	expression),	we	specifically	depleted	T	cells	to	assess	the	tumor	cell-intrinsic	 effects	 of	 cytokine	 treatment	 better.	 Consistent	 with	 in	 vitro	 results,	 these	observations	indicate	that	combining	MEKi	and	cytokines	results	in	the	most	significant	loss	of	 tumor	cell	 viability	(Fig.	2.11C).	 PD-1	blockade	 is	a	known	 inducer	of	 IFNγ	and	TNFα	secretion	 by	 T	 cells,	 including	 in	 the	 LKR	 model	 20,223.	 PD-1	 blockade	 induced	 tumor	regression	in	a	subset	of	LKR	tumor-bearing	mice	(Fig.	2.11D).	However,	we	found	that	the	combination	of	PD-1	blockade	and	MEKi	treatment	resulted	in	profound	tumor	regression	in	all	 treated	mice	(Fig.	2.11D).	Although	these	results	do	not	directly	 implicate	roles	for	
	64 
TNFα	or	 IFNγ,	 they	nonetheless	 suggest	 that	 immunotherapeutics	known	 to	 induce	 their	expression	can	synergize	with	MEKi	in	the	induction	of	anti-tumor	responses.		
	
Fig.	2.11	TNFα	and	IFNγ	synergize	with	MEKi	to	suppress	lung	cancer	in	vivo.	
0 4 8 1 2 1 6
-1 0 0
0
1 0 0
2 0 0
3 0 0
4 0 0
C
h
a
n
g
e
 F
ro
m
 B
a
s
e
li
n
e
(%
)
U T (n = 3 )
T R A  1 m g /k g (n = 3 )
* * * *
L K R
T R A  3 m g /k g (n = 3 )
* * * *
t im e (d a y s ) D M
S O T R
A
3 5 0
4 0 0
4 5 0
5 0 0
5 5 0
6 0 0
6 5 0
T N F R 1
L K R -M IG  tu m o r  C D 4 5 -G F P + T N F R 1 +  c e lls
M
F
I
*
D M
S O
+ P
B S
T R
A  
1m
g /
k g
a P
D -
1
T R
A +
a P
D -
1
-1 0 0
0
1 0 0
2 0 0
3 0 0
4 0 0
6 0 0
8 0 0
C
h
an
g
e 
F
ro
m
 B
as
el
in
e(
%
)
* *
n s
n s
D M
S O
+ P
B S
T R
A +
P B
S
D M
S O
+ I
F N
g+
T N
F
a  
0 .
5 u
g
T R
A +
IF
N
g+
T N
F
a  
0 .
5 u
g
-1 0 0
0
1 0 0
2 0 0
3 0 0
4 0 0
C
h
a
n
g
e
 F
ro
m
 B
a
s
e
li
n
e
(%
)
* * * *
*
n s
A B
C D
	65 
(A)	Different	dosage	of	trametinib	(TRA)	impact	on	growth	of	subcutaneous	LKR	tumors	in	129/sv	mice.	(B)	In	vivo	cell	surface	expression	of	TNFR1	detected	by	flow	cytometry.	GFP-expressing	LKR	cells	(LKR-MIG)	were	injected	in	129/sv	mice;	after	14	days,	mice	received	2	days	of	1	mg/kg	of	TRA	oral	gavage.	Tumor	tissue	was	dissected	and	stained	with	mouse	TNFR1-PE	antibody,	and	MFIs	of	TNFR1-PE	staining	on	 GFP	 positive	 cells	 were	 plotted.	 (C)	 Impact	 of	 continuous	 TRA	 and	 3	 consecutive	 intratumoral	injections	 of	 TNFα/IFNγ	 on	 growth	 of	 subcutaneous	 LKR	 tumors.	 Experiment	 scheme	 is	 shown,	bioluminescence	 imaging	was	 taken	 at	 days	 11	 and	 14.	 Total	 flux	 of	 photons	 of	 individual	mice	was	calculated	and	normalized	to	the	value	at	the	beginning	of	treatment.	Mean	±	SD	are	overlaid	as	error	bars.	One-way	ANOVA	and	a	post	hoc	Dunnett’s	multiple-comparison	test	were	performed.	(D)	TRA	and	anti-PD-1	antibody	(aPD-1)	effect	on	growth	of	subcutaneous	LKR	tumors	in	129/sv	mice	using	the	indicated	treatment	scheme.	Plot	showing	tumor	volume	change	from	baseline	at	the	experiment	endpoint	(14	days	of	TRA	treatment).	Tumor	volumes	were	measured	and	calculated	based	on	length	x	length	x	width/2	and	normalized	 to	 the	volume	at	 the	beginning	of	 treatment	 (day	0).	Change	of	 -100%	indicates	complete	tumor	rejection.	Significance	was	determined	using	one-way	ANOVA	and	a	post	hoc	Dunnett’s	multiple-comparison	test.	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.001.	ns:	not	significant.			
Enhancement	of	cell	cycle	arrest	and	apoptosis	by	MEKi	and	cytokine	treatment	is	
broadly	evident	in	lung	cancer	cells	We	 showed	 above	 that	 multiple	 human	 lung	 cancer	 and	 melanoma	 cell	 lines	upregulate	TNFR1	expression	upon	MEKi	treatment.	We	next	tested	whether	the	cytokine	and	MEKi	effects	on	viable	cell	numbers	observed	in	A549	and	LKR	were	generalizable	to	the	additional	human	lung	cancer	cell	lines	PC-9,	H1437,	HCC44,	and	H23.	Viable	cell	numbers	were	reduced	most	substantially	in	the	combined	presence	of	TNFα	+	IFNγ	and	MEKi	(Fig.	
2.12A).	The	combination	of	cytokines	and	MEKi	synergistically	reduced	viable	cell	numbers,	as	determined	by	the	Bliss	score	in	these	lung	cancer	lines	(Fig.	2.12C).	Unexpectedly,	TNFα	and	IFNγ	did	not	repress	cell	numbers	in	melanoma	cell	lines	(Fig.	2.12B),	and	cytokines	combined	 with	 MEKi	 did	 not	 enhance	 the	 MEKi	 inhibitory	 effect	 (Fig.	 2.12B,	 C).	 These	results	indicate	that	sensitivity	to	TNFα	+	IFNγ	and	synergy	with	MEKi	occur	in	the	lung	but	not	 in	melanoma	 cells.	As	 observed	with	 trametinib,	 treatment	 of	A549	 and	HCC44	with	additional	MEKi	and	TNFα	+	IFNγ	also	significantly	reduced	viable	cell	numbers	in	A549	and	HCC44	(Fig.	2.12D).		
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Fig.	2.12	Melanoma	cells	and	lung	cancer	cells	respond	differently	to	MEKi	and	cytokine	treatment.	
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(A-B)	 Cell	 proliferation	 of	 human	 lung	 cancer	 cell	 lines	 A549,	HCC44,	H1437,	 PC-9,	 and	H23	 (A)	 and	melanoma	cell	 lines	1205Lu,	WM164,	WM9,	and	WM793	(B)	after	 indicated	treatments	as	 in	Fig	2.8B,	except	that	only	the	combined	presence	of	TNFα	+	IFNγ	is	shown.	Cell	numbers	were	counted	on	day	4	for	each	cell	line	and	normalized	to	untreated	cells.	(C)	Synergy	between	TRA	and	cytokines	was	measured	using	Bliss	score;	heatmap	showing	selected	cell	 lines	used	 in	A	and	B	after	 indicated	 treatments.	 (D)	Impact	of	MEK	inhibitors	and	cytokines	(TNFα	and	IFNγ)	on	A549	(left)	and	HCC44	(right)	growth	in	vitro.	Cobi:	cobimetinib,	Bini:	binimetinib/MEK162)	and	AZD:	AZD8330.	3	X	104	cells	were	seeded	into	6-well	plates	with	indicated	treatments.	Viable	cell	numbers	were	counted	on	day	4	(A549)	or	day	2	(HCC44)	and	normalized	to	untreated	(UT)	cells.	The	concentration	of	each	cytokine	(TNFα,	IFNγ)	was	2	ng/ml.	Significances	were	determined	using	one-way	ANOVA	and	a	post	hoc	Tukey’s	multiple-comparison	test.	****p	<	0.0001.	ns:	not	significant.		 Consistent	with	the	above	results,	cytokines	combined	with	MEKi	treatment	led	to	a	significant	reduction	in	S-phase	cells	in	two	of	the	three	lung	cancer	cell	lines	tested	(Fig.	
2.13A).	We	next	determined	the	apoptotic	sensitivity	of	these	lung	cancer	cells	to	MEKi	and	cytokine	 treatment.	 In	 the	 highly	MEKi	 sensitive	melanoma	 cell	 line	WM164,	 a	 dramatic	increase	in	CC3	generation	was	evident	after	10	nM	MEKi		treatment	(Fig.	2.13B).	In	contrast,	10	nM	MEKi	induced	only	a	low	level	of	CC3	generation	in	lung	cancer	cell	lines;	this	level	was	only	moderately	increased	by	100	nM	MEKi.	Treatment	of	lung	cancer	cells	with	TNFα	+	 IFNγ	 also	 induced	 little	 CC3	 generation,	 however	 interestingly,	 the	 combination	 of	cytokines	 and	 MEKi	 dramatically	 enhanced	 CC3	 levels	 (Fig.	 2.13B;	 see	 boxed	 lanes),	consistent	with	the	decrease	in	viable	cells	observed	after	this	combination	treatment	(Fig.	
2.12A).	 In	these	cell	 lines,	 the	overall	CC3	levels	rather	than	specifically	the	p19	and	p17	forms	were	associated	with	a	loss	of	viable	cells.		Together	with	the	above	findings	in	A549	and	LKR,	these	results	indicate	that,		unlike	BRAF	mutant	melanoma	which	is	highly	sensitive	to	MEK	signaling	targeting,	 lung	cancer	cells	 are	 largely	 resistant	 to	 apoptosis	 induction	 by	 MEKi,	 their	 apoptotic	 sensitivity	 is	substantially	increased	in	the	presence	of	TNFα	+	IFNγ.			
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Figure	2.13	Enhancement	of	 cell	 cycle	arrest	and	apoptosis	by	MEKi	and	cytokine	 treatment	 is	
broadly	evident	in	lung	cancer	cells.	(A)	Cell	cycle	analysis	of	PC9,	HCC44,	and	H23	after	treatments	indicated,	as	in	Fig.	2.8C.	Comparisons	were	made	using	a	chi-squared	test	with	Bonferroni	correction	of	S	 versus	 G1/G2	 frequencies.	 Plot	 shows	 representative	 result	 from	 3	 independent	 experiments.	 (B)	Western	blot	showing	comparison	between	apoptosis	induced	by	TRA	plus	cytokines	in	lung	cancer	cell	lines	and	TRA-induced	apoptosis	in	melanoma	cell	line	WM164.	Single	treatment	with	TRA	and	cytokines	in	lung	cancer	lines	is	indicated	in	blue	rectangles	and	combined	treatment	in	red	rectangles.			
Discussion	The	studies	presented	here	demonstrate	a	novel	and	unexpected	link	between	MEK	inhibitors	(MEKi)	and	TNFα	signaling	in	lung	cancer	cells.	We	show	that	the	upregulation	of	cell	surface	TNFR1	expression	is	a	general	and	widespread	effect	of	MEK	inhibition	because	it	was	evident	across	an	array	of	human	and	mouse	cancer	cells	from	different	tumor	types	and	with	distinct	driver	oncogene	mutations.	The	upregulation	of	TNFR1	at	the	cell	surface	
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not	only	enhanced	TNFα-induced	responses	but	also	those	jointly	controlled	by	TNFα	and	IFNγ.	 Crucial	 amongst	 them	 were	 gene	 expression,	 cell	 cycle	 arrest,	 and	 cell	 death.	 In	multiple	human	lung	cancer	cell	lines,	we	show	that	the	combination	of	cytokines	and	MEKi	induced	the	highest	levels	of	cell	cycle	arrest	and	apoptosis.	In	vivo	studies	performed	with	human	A549	demonstrated	that	TNFR1	deficiency	attenuated	the	MEKi	anti-tumor	response.	Interestingly,	TNFα	and	IFNγ	did	not	induce	growth	suppression	or	enhance	MEKi-induced	growth	 suppression	 in	 melanoma	 cells.	 The	 underlying	 reason	 for	 this	 difference	 is	 not	presently	 clear	 but	 may	 indicate	 an	 intrinsic	 resistance	 of	 melanoma	 cells	 to	 growth	suppression	and	cell	death	induction	by	these	cytokines.	A	recent	study	showed	relatively	low	 trametinib	 treatment	 response	 (12%)	 in	NSCLC	with	KRAS	mutations	 61.	Our	 results	suggest	that	combining	MEKi	with	agents	that	promote	TNFα	and	IFNγ	expression,	such	as	checkpoint	 blockade	 or	 T	 cell	 adoptive	 cell	 therapy	 (ACT),	 may	 help	 achieve	 increased	benefit	 in	 lung	 cancer	 patients.	 In	 this	 setting,	 distinct	 mechanisms	 may	 cooperatively	promote	anti-tumor	responses	through	a	synergistic	increase	in	the	expression	of	immune	function	genes,	and	most	important,	the	potentiation	of	growth	suppression	and	cell	death.	Furthermore,	 TNFα	 and	 IFNγ	 expression	 and/or	 pathway	 activation	 could	 provide	 a	predictive	and	prognostic	biomarker	of	MEKi	treatment	response.	Our	results	indicate	that	a	crucial	aspect	of	cross-talk	between	MEKi	and	TNFα	/	IFNγ	is	 the	 augmentation	 of	 cell	 death	 and	 is	 mediated	 by	 caspase-induced	 apoptosis.	 At	trametinib	 concentrations	 achieved	 in	 patients	 (~10–12nM)	 224,	 this	 agent	 essentially	induced	 no	 CC3	 activation	 in	 lung	 cancer	 cells.	 However,	 at	 the	 same	 concentrations,	trametinib	combined	with	TNFα	+	IFNγ	induced	robust	CC3	activation	coincident	with	a	loss	of	viable	cells.	In	vivo	studies	indicate	that	high	levels	of	these	cytokines	(e.g.	by	cytokine	
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injection	or	potentially	induced	by	PD-1	blockade)	enhance	tumor	regression	compared	to	individual	 treatments.	 This	 is	 consistent	 with	 our	 findings	 showing	 a	 cytokine	 dose-dependent	 increase	 in	apoptotic	marker	CC3,	 suggesting	 that	 synergy	between	MEKi	and	cytokines	will	be	enhanced	in	proportion	to	cytokine	levels.	In	all	lung	cancer	cell	lines	tested,	we	have	observed	that	the	combination	of	MEKi	with	both	TNFα	and	IFNγ	is	required	for	maximal	 loss	 of	 viable	 cells.	 However,	 several	 aspects	 of	 these	 findings	 require	 further	investigation:	 first,	 in	 LKR	 cells,	 these	2	 cytokines	had	distinct	 effects	 on	CC3	generation	individually	and	when	combined	with	MEKi.	Thus,	the	contribution	of	individual	cytokines	and	synergy	between	them	in	apoptosis	induction	with	MEKi	requires	further	study	in	LKR	as	 well	 as	 in	 additional	 cell	 types	 in	 order	 to	 define	 the	 underlying	mechanisms	 better.	Second,	we	have	surmised	that	the	increase	in	TNFα	responses	through	TNFR1	upregulation	enhances	gene	expression,	 cell	 cycle	arrest,	 and	cell	death	 responses	 jointly	 regulated	by	TNFα	+	IFNγ.	However,	 it	remains	to	be	determined	whether	MEKi	also	impacts	the	IFNγ	pathway,	 irrespective	 of	 the	 effect	 on	 the	TNFα	pathway.	 Although	MEKi	 did	 not	 impact	STAT1	 activation	 by	 IFNγ	 in	A549,	 it	 is	 nonetheless	 possible	 that	more	 subtle	 cross-talk	exists	between	MEKi	and	the	IFNγ	pathway.	Finally,	TNFR1	deficiency	in	A549	led	to	partial	resistance	to	MEKi.	Although	exogenous	cytokine	addition	universally	synergizes	with	MEKi	to	reduce	lung	cancer	cell	viability,	it	remains	to	be	determined	whether	TNFR1	deficiency	is	 also	 sufficient	 for	 conferring	 resistance	 to	 MEKi	 treatment.	 The	 direct	 systemic	administration	of	TNFα	and/or	 IFNγ	 is	expected	 to	be	quite	 toxic.	Type	1	 IFN	(e.g.	 IFNα)	shares	many	key	features	with	type	II	IFN	(IFNγ),	and	importantly,	IFNα	has	been	in	clinical	use	for	cancer	treatment	for	many	years.	Interestingly,	we	found	that	similar	to	IFNγ,	IFNα	also	 synergized	 with	 TNFα	 and	MEKi	 in	 enhancing	 gene	 expression	 and	 decreasing	 cell	
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viability	(Fig.	2.14).	Although	this	combination	needs	to	be	first	tested	in	preclinical	models,	if	effective,	 it	can	be	explored	 in	 the	clinical	setting	as	a	novel	combination	treatment	 for	cancer.			
		
Figure	2.14.	(A)	CXCL10	mRNA	expression	in	A549	was	determined	by	qPCR	after	indicated	treatments;	gene	expression	levels	were	normalized	to	unstimulated	cells.	Significances	were	determined	using	one-way	ANOVA	and	a	post	hoc	Tukey’s	multiple-comparison	test.	****p	<	0.0001.	(B)	Impact	of	MEK	inhibitors	and	cytokines	(TNFα	and	IFNα)	on	A549	and	HCC44	growth	in	vitro.	Experiments	were	performed	the	same	way	as	in	Fig.4B	and	Fig.S9.	Significances	were	determined	using	one-way	ANOVA	and	a	post	hoc	Tukey’s	multiple-comparison	test.	****p	<	0.0001.				 Sensitivity	to	TNFα	induced	apoptosis	is	controlled	by	the	balance	of	pro-death	and	-survival	pathways.	NF-κB	functions	in	suppressing	both	TNFα-and	IFNγ-induced	apoptosis	and	necroptosis	cell	death	pathways	225,226.	However,	MEKi	enhances	NF-κB	activation	while	concomitantly	 promoting	 cell	 death.	 One	 possibility	 is	 that	 the	 magnitude	 of	 cell	 death	pathway	enhancement	by	MEKi	and	cytokines	is	such	that	it	cannot	be	controlled	by	NF-κB	pro-survival	 functions.	 In	 human	 lung	 cancer	 cell	 lines,	 TNFα	 and	 IFNγ	 cooperatively	promoted	cell	cycle	arrest	with	MEKi.	Therefore,	loss	of	viable	human	lung	cancer	cells	after	
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combined	treatment	with	cytokines	and	MEKi	likely	results	from	both	cell	cycle	arrest	and	cell	death.	In	contrast,	MEKi	combined	with	cytokines	did	not	enhance	cell	cycle	arrest	 in	mouse	 LKR	 cells,	 where	 an	 increase	 in	 cell	 death	 appears	 to	 be	 the	 dominant	 pathway.	Previous	 studies	 showed	 that	 these	 cytokines	 synergistically	 induce	 cancer	 cell	 growth	suppression	 through	 cell	 cycle	 arrest	 and	 senescence	 induction	 that	 is	 mediated	 by	 the	CDK/Rb	pathway	 190.	Although	we	did	not	 observe	 a	 clear	 cell	 cycle	 arrest	 phenotype	 in	human	lung	cancer	cell	lines	after	treatment	with	TNFα	and	IFNγ,	it	is	possible	that	the	MEKi-induced	increase	in	cytokine	signaling	enhances	growth	suppression	through	the	CDK/Rb	pathway.
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CHAPTER	3	–	MEK	INHIBITORS	ENHANCE	T	CELL	ANTI-TUMOR	EFFICACY		
Abstract	The	treatment	of	metastatic	melanoma	patients	with	autologous	tumor-infiltrating	lymphocytes	(TILs)	shows	robust,	reproducible	therapeutic	efficacy.	However,	this	approach	has	 several	 limitations;	 patients	 can	 develop	 resistance	 quickly,	 and	 the	 response	 varies	among	 patients.	 This	 approach	 has	 not	 been	 fully	 tested	 in	 non-small-cell	 lung	 cancer.	Although	 the	 direct	 lysis	 of	 antigen-expressing	 cancer	 cells	 is	 an	 essential	 part	 of	 T	 cell	therapy,	cytokines	secreted	by	activated	T	cells	can	also	induce	cell	death	and	contribute	to	an	 overall	 anti-tumor	 effect	 183,189,190.	 However,	 the	 contribution	 of	 cytokines	 and	 their	potential	 has	not	been	 fully	 evaluated.	 In	 this	 study,	we	developed	an	 in	vitro	 co-culture	system	that	utilizes	CD8+	T	cells	obtained	from	OT-1	transgenic	mice	with	specificity	for	the	OVA257-264-peptides	in	association	with	class	I	MHC	(kb-OVA)	and	firefly	luciferase	(TK)	expressing	 LKR	 cells	 to	 evaluate	 the	 T	 cell	 cytokine-mediated	 anti-tumor	 effect	 can	 be	enhanced	by	MEKi.	Importantly,	the	overall	T	cell	anti-tumor	effect	was	significantly	reduced,	and	the	loss	of	TNFα	and	IFNγ	signaling	eliminated	the	synergy	with	MEKi.	These	findings	provided	 further	 evidence	 for	 developing	 a	 pre-clinical	model	 and	 a	 clinical	 approach	 to	combine	TIL	therapy	with	MEKi	for	lung	cancer	treatment.			
Introduction	Adoptive	 cell	 transfer	 (ACT)	 based	 on	 autologous	 T	 cells	 derived	 from	 tumor-infiltrating	 lymphocytes	 (TILs)	 is	 a	 therapeutic	 approach	 comprising	 the	 isolation	 of	
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autologous	 tumor-infiltrating	 lymphocytes	and	 in	vitro	culture	with	 lymphokines	such	as	interleukin-2	(IL-2);	upon	administration	in	vivo,	T	cells	re-infiltrate	the	tumor	to	 initiate	tumor	cell	lysis	and	induce	tumor	regression	227,228.	This	promising	approach	led	to	a	high	response	rate	in	melanoma	patients	(~50%)	but	is	less	effective	in	many	other	cancer	types,	including	 lung	 cancer	 229-232.	 One	 important	 reason	 for	 this	 lack	 of	 effectiveness	 is	 the	insufficient	number	and/or	persistence	of	TILs	reactive	to	tumor-expressed	antigens	232.	On	the	other	hand,	resistance	or	relapse	can	be	another	limitation	of	TIL	therapy	because	only	cells	that	express	tumor	antigens	can	be	recognized	and	subject	to	T	cell	cytolysis;	this	can	put	a	selective	pressure	on	the	cancer	cell	population	and	allow	expansion	of	colonies	that	lack	intrinsic	antigen	and	HLA	expression,	or	induces	immunoediting	that	leads	to	escape	and	acquired	resistance	233.		Our	 studies	 in	 the	 previous	 chapter	 have	 established	 the	 concept	 that	MEKi	 plus	cytokines	 can	 induce	 synergistic	 anti-tumor	 efficacy.	 The	 TNFα	 and	 IFNγ	 produced	 by	transferred	T	cells	and	other	components	in	the	tumor	microenvironment	could	potentially	exhibit	 enhanced	 cytotoxic	 potency	 when	 MEKi	 is	 present,	 providing	 an	 opportunity	 to	improve	the	efficacy	of	T	cell-based	therapeutics	for	lung	cancer	patients.	The	motivation	of	this	study	was	to	establish	an	in	vitro	system	to	estimate	this	potential.	OT-1	T	cells	are	CD8+	T	cells	produced	by	transgenic	mouse	of	which	T	cell	receptor	was	designed	to	recognize	ovalbumin	residues	257-264	presented	by	H2Kb	(Kb-OVA),	those	cells	can	be	activated	in	vitro	 after	 antigen	 stimulation.	 Using	 an	 OT-1	 T	 cell	 and	 Kb-OVA	 target	 cell	 model,	 we	showed	that	indirect	killing	by	through	cytokine-induced	cell	death	contributes	significantly	to	 overall	 T	 cell	 cytotoxicity,	which	 can	 be	 synergistically	 enhanced	 in	 combination	with	MEKi.		
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Methods	
Cell	lines	TNFR1	 and	 IFNγR1	 were	 knocked	 out	 in	 LKR	 cells	 using	 mouse	 TNFR1	 and	 IFNγR1	CRISPR/Cas9	knockout	plasmids	purchased	from	Santa	Cruz	Biotechnology.	The	protocol	for	CRISPR/Cas9	knock	out	was	described	in	the	Chapter	2	methods.	To	quantify	the	relative	cell	 number,	 firefly	 luciferase	 was	 expressed	 in	 both	 LKR	 parental	 cells	 (LKR-TK)	 and	receptor	 double	 knockout	 cells	 (LKR-DKO-TK).	 Finally,	 we	 expressed	 Kb-OVA	 (a	 single	polypeptide	 encoding	 H-2Kb,	 β2-M,	 and	 the	 model	 antigen	 ovalbumin	 (OVA257-264)	SIINFEKL	peptide	recognized	by	OT-1	T	cells)	in	those	cells	(LKR-TK-KBOVA,	LKR-DKO-TK-KBOVA),	and	OVA	expression	was	validated	using	flow	cytometry.	
OT-1	T	cell	activation	and	isolation	OT-1	mouse	spleens	were	collected	for	T	cell	in	vitro	activation.	Each	spleen	was	ground	on	a	70-uM	mesh	with	1	ml		of	PBS;	after	PBS	rinsing,	splenocytes	were	centrifuged	at	2,000	rpm	for	5	minutes,	followed	by	5	ml	of	ACK	buffer	incubation	for	4	minutes	to	lyse	the	red	blood	cells.	The	reaction	was	then	stopped	by	adding	5	ml	of	complete	media.	After	5	minutes	at	2,000	rpm	centrifugation,	 the	remaining	cells	were	resuspended	 in	1	mL	T	cell	culture	media.	Splenocytes	were	counted	and	diluted	to	5	x105	/ml	and	seeded	into	24-well	plates	with	the	presence	of	1	ug/ml	OVA257–264	peptide	(SIINFEKL,	AS-60193-5,	Anaspec)	and	10	 IU	 IL-2.	 On	 the	 third	 day,	 the	 culture	 supernatant	 containing	 cytokines	 produced	 by	activated	 T	 cells	 was	 collected,	 and	 CD8+	 T	 cells	 were	 harvested	 and	 enriched	 using	 a	negative	purification	kit	(Stem	Cell	Technologies).	
	76 
Target-effector	co-culture	system	and	luciferase	detection	For	the	target-effector	co-culture,	5,000	luciferase-expressing	LKR	cells	were	seeded	in	a	96-well	plate.	On	the	next	day	after	the	cells	had	attached,	activated	and	purified	CD8	T	cells	were	added	to	LKR	cells	at	0.1:1,	1:1,	5:1,	and	10:1	ratios	with	or	without	10	nM	TRA.	For	supernatant	incubation,	the	supernatant	that	was	collected	on	the	third	day	of	splenocyte	culture	was	diluted	at	1:4	and	1:20	in	fresh	media	and	added	to	target	cells	with	or	without	10	nM	TRA.	After	48	h,	culture	media	was	removed,	and	T	cells	were	washed	off	using	PBS;	target	cells	were	lysed	in	plates,	followed	by	luciferase	bioluminescent	measurement.	Raw	bioluminescent	intensity	(BLI)	was	normalized	to	the	untreated	group	(UT)	within	each	cell	line.			
Results	
TNFα	and	IFNγ	signaling	does	not	affect	T	cell-mediated	antigen-specific	killing		The	T	cell-mediated	anti-tumor	effect	comprises	direct	cytolytic	activity	as	well	as	cytokine-induced	cell	death.	The	former	process	occurs	via	MHC	antigen	recognition	of	TCR	that	requires	expression	and	presentation	of	specific	tumor	antigens,	whereas	the	latter	also	impacts	 non-specific	 tumor	 cells	 that	 lack	 specific	 antigen	 expression;	 this	 important	bystander	 killing,	 however,	 is	 often	 overlooked.	 To	 estimate	 the	 relative	 contribution	 of	cytokine-mediated	bystander	killing	and	boost	its	potential,	we	implemented	an	in	vitro	co-culture	system	in	which	the	tumor	cell	growth	is	quantifiable	using	a	firefly	bioluminescence	assay.	In	this	system,	we	utilized	Kb-OVA	and	firefly	luciferase	expressing	LKR	cells	as	the	specific	target	of	OT-1	T	cells	and	parental	LKR	as	the	non-specific	target.	Flow	cytometry	was	 performed	 before	 and	 after	 T	 cell	 isolation	 on	 the	 third	 day	 of	 splenocyte	 culture,	
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ensuring	that	OVA-specific	CD8	T	cells	(Va2/Vb5+	CD8+)	were	successfully	activated	and	purified	(Fig.	3.1A).			
	 	
Figure	3.1.	TNFα	and	IFNγ	signaling	does	not	affect	T	cell-mediated	antigen-specific	killing.	
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(A)	Flow	cytometry	was	performed	before	(upper	panel)	and	after	(lower	panel)	negative	isolation	on	day	3	of	splenocyte	culture	to	evaluate	the	T	cell	activity,	viability,	and	OVA	specificity.	(B)	5,000	luciferase	expressing	LKR	target	cells	were	seeded	in	a	96-well	plate;	the	next	day	after	cells	were	attached,	activated	OT-1	T	cells	were	added	into	the	plate	at	the	ratios	indicated	on	the	x-axis.	After	4	h	incubation,	cells	were	lysed	in	the	plate,	followed	by	luciferase	bioluminescent	measurement.	BLI	intensity	was	normalized	to	untreated	control	group	(0	on	x-axis)	within	each	cell	line.	All	conditions	were	performed	in	triplicate.	Significances	were	determined	using	two-way	ANOVA	and	ad	hoc	Tukey’s	multiple	comparisons.	*p	<	0.05,	**p	<	0.01.			
	
Figure	3.2.	MEKi	 enhances	 overall	 T	 cell	 anti-tumor	 effect	 through	modulating	TNFα	 and	 IFNγ	
signals.	
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(A)	5000	luciferase	expressing	LKR	target	cells	were	seeded	in	a	96-well	plate;	on	the	next	day	after	cells	attached,	activated	OT-1	T	cells	were	added	to	plate	at	the	ratios	indicated.	After	48	h	of	incubation,	cells	were	 lysated	 in	 the	 plate,	 followed	 by	 luciferase	 bioluminescent	 measurement.	 BLI	 intensity	 was	normalized	 to	untreated	 control	 group	 (UT)	within	each	 cell	 line.	 (B)	5000	 luciferase-expressing	LKR	target	cells	were	seeded	in	a	96-well	plate;	on	the	next	day	after	cells	attached,	supernatant	collected	on	the	third	day	of	SIINFEKL-stimulated	OT-1	splenocyte	culture	was	diluted	1:4	or	1:20	in	fresh	cell	culture	media	and	added	to	target	cells	with	or	without	10	nM	TRA.	After	48	h	of	incubation,	cells	were	lysated	in	the	plate,	followed	by	luciferase	bioluminescent	measurement.	BLI	intensity	was	normalized	to	untreated	control	group	(UT)	within	each	cell	line.	All	conditions	were	performed	in	triplicate.	Significances	were	determined	 using	 two-way	 ANOVA	 and	 ad	 hoc	 Dunnett’s	 multiple	 comparisons(with	 TRA	 10	 nM	 as	control	condition).	*p	<	0.05,	**p	<	0.01,	****p	<	0.0001.			 To	validate	the	co-culture	system,	we	first	measured	the	potency	of	T	cell-mediated	direct	cytolytic	activity	using	a	range	of	effector:target	ratios	(Fig.	3.1B)	due	to	the	fact	that	the	direct	killing	occurs	rapidly	upon	TCR	recognition	of	antigen.	The	co-culture	time	was	4	hours;	this	short-term	incubation	period	also	avoided	cytokine-mediated	non-specific	killing	becoming	a	confounding	 factor	 in	this	experiment,	a	process	that	we	found	takes	24	h	or	longer.		Indeed,	no	significant	difference	was	found	between	parental	cells	(LKR-TK-KBOVA)	and	TNFR1	IFNγR1-depleted	cells	(LKR-DKO-TK-KBOVA),	indicating	that	disabled	TNFα	and	IFNγ	signaling	do	not	affect	T	cell-mediated	direct	lysis	(Fig.	3.1B).	Furthermore,	the	result	showed	minimal	 cell	 number	 reduction	 for	parental	 cells	 (LKR-TK)	but	 an	effector	dose-dependent	effect	in	antigen-cells	(LKR-TK-KBOVA)	(Fig.	3.1B),	suggesting	effective	T	cell-mediated	cytolysis	on	specific	antigen-expressing	target	cells.	In	other	words,	we	expect	that	in	 a	 long-term	 (>24	 h)	 co-culture	 experiment,	 the	 reduced	 anti-tumor	 effect	 in	 TNFR1	IFNγR1-depleted	cells	will	most	likely	be	attributed	to	the	lack	of	cytokine-mediated	tumor	suppression	rather	than	a	deficiency	in	T	cell	cytolysis.			
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MEKi	enhances	overall	T	cell	anti-tumor	effect	through	modulating	TNFα	and	IFNγ	
signals	In	the	previous	chapter,	our	results	have	shown	that	exogenous	TNFα	and	IFNγ	can	start	to	induce	cell	death	within	48	h.	Antigen-stimulated	T	cells	keep	producing	cytokines	while	they	stay	active;	therefore,	when	tumor	cells	are	co-incubated	with	T	cells	for	a	longer	time	period	(48	h),	the	anti-tumor	effect	is	the	combined	effect	of	both	T	cell	direct	lysis	and	cytokine-induced	cell	death.	In	a	48-h	target	:	effector	cell	co-culture,	a	synergistic	tumor	cell	suppression	effect	with	MEKi	was	observed	in	intact	LKR	cells	(LKR-TK-KBOVA)	at	the	1:5	effector:target	 ratio,	 which	 was	 found	 to	 be	 an	 effective	 ratio,	 whereas	 in	 cells	 that	 are	deprived	 of	 TNFα	 and	 IFNγ	 signals	 (LKR-DKO-TK-KBOVA),	 part	 of	 the	 T	 cell-mediated	suppression	effect	was	lost	(T	cells	at	1:5	ratio	in	LKR-TK-KBOVA	versus	in	LKR-DKO-TK-KBOVA	group,	green	bars	in	histogram	of	Fig.	3.2A).	Importantly,	we	found	that	the	synergy	with	 MEKi	 is	 completely	 lost	 in	 the	 LKR-DKO-TK-KBOVA	 group,	 compared	 to	 LKR-TK-KBOVA	(the	difference	between	blue	and	green-blue	bars	within	the	group,	Fig.	3.2A).		Taken	 together,	 in	 this	 long	 term	 co-culture,	 a	 reduced	 anti-tumor	 effect	 was	observed	in	LKR-DKO-TK-KBOVA	due	to	the	loss	of	cytokine	signaling,	and	the	further	effect	boosted	by	MEKi	as	seen	in	LKR-TK-KBOVA	was	no	longer	present.	This	result	indicates	that	TNFα	and	IFNγ	signals	contribute	to	the	overall	T	cell	anti-tumor	effect,	and	this	effect	can	be	enhanced	by	MEKi	(Fig.	3.2A).	This	conclusion	led	to	the	design	of	the	next	experiment	in	which	target	cells	are	specifically	exposed	to	T	cell-secreted	cytokines.		 To	demonstrate	further	that	synergy	with	MEKi	is	through	cross-talk	with	cytokines	and	to	assess	whether	TNFα	and	IFNγ	are	the	major	anti-tumor	players	in	T	cell-produced	cytokines,	we	performed	another	experiment	with	the	same	setup,	except	that	we	replaced	
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purified	T	cells	with	supernatant	collected	on	day	3	of	splenocyte	culture.	Supernatant	was	diluted	 and	 added	 to	 target	 cells.	 This	 supernatant	 primarily	 comprises	 T	 cell	 cytokines	because	OT-1	T	cells	are	the	majority	live	cell	population	at	the	3rd	day	of	splenocyte	culture	
(Fig.	3.1A).	Although	activated	T	cells	produce	other	cytokines	such	as	IL-2	and	IFNα	that	impact	tumor	cell	growth,	the	contribution	of	TNFα	and	IFNγ	can	be	measured	by	comparing	parental	LKR	(LKR-TK-KBOVA)	cells	with	TNFR1	IFNγR1	double-knockout	cells	(LKR-DKO-TK-KBOVA).	The	result	showed	that	48	h	of	supernatant	incubation	significantly	reduced	the	target	cell	number,	suggesting	the	important	role	of	the	TNFα	and	IFNγ	anti-tumor	effect.		Importantly,	 MEKi	 synergistically	 enhanced	 the	 tumor	 cell	 suppression	 effect	 of	 the	supernatant.	In	receptor	knockout	cells	(LKR-DKO-TK-KBOVA),	the	anti-tumor	effect	of	the	added	supernatant	was	largely	impaired,	and	the	synergy	with	MEKi	was	lost	(Fig.	3.2B),	suggesting	that	TNFα	and	IFNγ	produced	by	activated	T	cells	are	the	primary	players	in	the	anti-tumor	effect,	which	can	be	further	enhanced	by	MEKi.	These	results	provide	a	rationale	for	the	development	of	MEKi	+	ACT	as	a	promising	therapeutic	approach.			
Discussion	Adoptive	 T	 cell	 transfer	 using	 autologous	 TILs	 had	 led	 to	 a	 high	 response	 rate	 in	melanoma	patients	(~50%)	but	is	less	effective	in	many	other	cancer	types,	including	lung	cancer.	The	studies	 in	 this	chapter	aim	to	 translate	our	key	 findings	described	 in	 the	 last	chapter	to	a	more	clinically	relevant	setting	and	assess	the	approach	of	combining	MEKi	and	TIL	 therapy	 for	 lung	 cancer	 treatment.	 In	 this	 study,	 we	 evaluated	 the	 anti-tumor	contributions	of	T	cell-derived	TNFα	and	IFNγ	and	their	synergy	potential	with	MEKi	in	vitro.	Using	the	OT-1	model	system,	our	results	showed	that	TNFα	and	IFNγ	secreted	by	activated	
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T	cells	contribute	significantly	to	the	T	cell	anti-tumor	effect,	and	this	effect	can	be	further	enhanced	by	MEKi,	providing	a	practical	relevance	of	our	proposed	concept	in	last	chapter.	Notably,	 although	 there	were	 concerns	 about	 the	 impact	 of	MEKi	 on	 T	 cell	 function	 and	viability	because	MAPK	signaling	is	vital	in	T	cell	development	and	activation,	more	recent	work	has	provided	evidence	showing	that	MEKi	improves	T	cell	function	and	longevity	when	administrated	in	vivo64.	Another	important	benefit	of	the	MEKi	+	TIL	approach	compared	to	immune	therapy	alone	is	overcoming	resistance.	The	bystander	killing	effect	by	cytokines	does	 not	 rely	 on	 antigen	 specificity;	 this	 effect	 can	be	 significantly	 enhanced	by	MEKi	 to	eliminate	 clones	 that	 are	 able	 to	 escape	 from	 T	 cell	 antigen	 recognition.	 When	 MEKi	maintains	 membrane	 TNFR1	 at	 a	 high	 level,	 cells	 become	 more	 susceptible	 to	 T	 cell	cytotoxicity.	Induced	apoptosis	could	also	generate	a	more	immunogenic	microenvironment,	which	 eventually	 forms	 a	 reinforcement	 cycle	 of	 anti-tumor	 immunity.	 MEKi	 +	 TIL	may	provide	an	alternative	solution	to	MEKi	+	anti-PD-1	because	autologous	TILs	may	be	more	reactive	to	tumors	and	produce	more	TNFα	and	IFNγ	in	the	tumor	microenvironment—this	combination	may	also	reduce	toxicity	compared	to	MEKi	+	anti-PD-1	(discussed	in	page	28)	because	TIL-related	toxicity	is	less	common	than	in	other	types	of	immunotherapies.		In	addition	to	TNFα	and	IFNγ,	activated	CD4	and	CD8	T	cells	produce	a	repertoire	of	cytokines	 with	 diverse	 functions;	 it	 remained	 undetermined	 whether	 there	 is	 cross-talk	between	MEKi	and	other	cytokines	that	modulate	the	immune	response	and	regulate	anti-tumor	immunity.	Although	we	have	shown	here	that	among	T	cell-secreted	products,	TNFα	and	IFNγ	plays	a	predominant	anti-tumor	role	(particularly	in	the	presence	of	MEKi),	it	is	still	important	to	perform	more	comprehensive	and	quantitative	assays	to	elucidate	the	role	of	 other	 components	 that	 was	 contribute	 to	 the	 cross-talk.	 Quantifying	 TNFα	 and	 IFNγ	
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produced	in	the	tumor	microenvironment	will	improve	the	estimation	of	the	overall	synergy	and	anti-tumor	effect	that	could	be	achieved	in	combination	therapy.		As	a	step	further,	future	studies	will	be	required	to	establish	mouse	models	to	assess	this	 combinatorial	 opportunity	 in	 vivo.	 It	 is	 important	 to	 also	 compare	 the	 response	and	effect	 in	 immunogenic	 tumor	 versus	 tumor	 with	 more	 heterogeneity,	 enabling	 the	assessment	 of	 the	 bystander	 killing	 effect,	 which	 could	 be	 important	 in	 overcoming	resistance	and	relapse.	Additionally,	combining	treatment	with	other	strategies	could	also	further	strengthen	the	anti-tumor	effect.	Recent	work	from	David	W.	Vredevoogd	et	al.	also	found	that	TNFα	signaling	contributes	significantly	to	T	cell	antitumor	activity,	especially	in	tumors	 that	 harboring	 resistance	 to	 IFNγ.	 The	 authors	 used	 genome-wide	 CRISPR-Cas9	screening	 and	 identified	 TRAF2	 as	 a	 target	 to	 lower	 the	 cancer	 cell	 sensitivity	 to	 TNFα;	TRAF2	inactivation	causes	tumors	to	undergo	RIPK1-dependent	cell	death	in	response	to	T	cell-derived	TNFα	178.	Those	results	are	in	agreement	with	our	discoveries,	suggesting	that	the	combination	of	MEKi	with	the	inhibition	of	TRAF2-cIAP	complex	using	SMAC	mimetic	(e.g.	 birinapant)	 might	 even	 further	 potentiate	 the	 response	 to	 immune	 therapies	 that	produce	TNFα	and	IFNγ.		
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CHAPTER	4	–	CONCLUSIONS	AND	FUTURE	DIRECTIONS		 The	success	of	immunotherapy	in	melanoma	and	lung	cancer	has	triggered	a	variety	of	combinatorial	approaches,	such	as	different	immune	checkpoint	blockades,	chemotherapy,	and	kinase-targeting	agents.	The	major	challenge	of	developing	those	novel	therapeutics	is	the	lack	of	knowledge	of	the	underlying	mechanisms;	approaches	that	are	based	on	evidence	and	solid	rationale	are	not	only	important	for	clinical	trial	success	but	also	for	preventing	unnecessary	waste	of	resource	and	missed	treatment	opportunity	for	patients.	Previously,	several	 clinical	 studies	 revealed	 that	MEKi	 could	 potentially	 improve	 the	 tumor	 immune	microenvironment,	but	no	detailed	investigation	was	done	with	regard	to	the	mechanisms	of	how	cancer	cells	respond	to	this	cross-talk	67-69.	The	studies	presented	in	this	dissertation	provide	insightful	mechanisms	and	proof	of	the	concept	for	a	novel	vulnerability	of	epithelial	cancer	 cells	 treated	 with	 inhibitors	 of	 the	 RAS	 downstream	 kinase	 MEK,	 which	 have	 a	synergistic	 anti-tumor	 effect	with	 immunotherapy.	We	 demonstrate	 that	 upregulation	 of	TNFα	 and	 IFNγ	 signaling	 by	MEKi	 not	 only	 leads	 to	 an	 increased	 expression	 of	 immune	surveillance	 genes	 but	 also	 significantly	 enhances	 the	 growth-suppressive	 and	 apoptotic	vulnerability	of	cancer	cells.	Lung	cancer	cells	minimally	sensitive	to	MEKi	were	rendered	highly	susceptible	to	this	agent	in	the	presence	of	TNFα	and	IFNγ.	Our	in	vivo	results	further	demonstrate	the	crucial	role	of	these	cytokines	for	MEKi	therapeutic	efficacy.	We	propose	that	epithelial	cancers,	such	as	lung	cancer,	can	be	rendered	sensitive	to	MEKi	in	the	presence	of	these	key	cytokines,	and	we	provide	a	strong	mechanistic	rationale	for	combining	MEKi	with	immunotherapeutics	that	enhance	the	expression	of	TNFα	and	IFNγ.		
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Figure	4.1.	(A)	Impact	of	AMG510,	IFNγ,	and	TNFα	on	HCC44	growth	in	vitro.	1	X	104	cells	were	seeded	into	6-well	plates	and	incubated	with	100	nM	AMG	with	or	without	2	ng/ml	IFNγ	and/or	TNFα	for	the	next	4	days;	viable	cell	numbers	were	counted	on	day	4	and	normalized	to	untreated	(UT).	Plot	represents	mean	±	SD	of	3	replicates,	and	significance	was	determined	using	one-way	ANOVA	and	a	post	hoc	Tukey’s	multiple-comparison	test	and	is	shown	for	indicated	comparisons.	****p	<	0.0001.	(B)	TNFRSF1A	mRNA	expression	 in	 A549	 was	 determined	 by	 qPCR.	 mRNA	 samples	 were	 obtained	 from	 the	 experiment	described	in	Fig.	2.6.				 This	novel	concept	led	to	several	interesting	follow-up	hypotheses	that	are	currently	under	investigation.	Firstly,	one	important	finding	of	this	study	is	that	cell-surface	TNFR1	upregulation	and	its	biological	effects	induced	by	MEKi	is	a	rather	universal	effect;	13	of	the	experimented	 agents	 that	 target	 the	 MEK-ERK	 pathway	 have	 shown	 target	 gene	upregulation;	further	validation	using	4	MEK	inhibitors	as	well	as	a	BRAF	inhibitor	has	also	shown	that	 this	effect	 is	dose-dependent.	TNFR1	is	also	widely	upregulated	by	MEKi	 in	a	range	of	cancer	cell	 lines,	suggesting	that	our	proposed	approach	could	bring	therapeutic	benefit	to	a	broad	range	of	patients.	It	is	hypothesized	that	agents	that	hit	other	targets	of	
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the	 RAS-RAF-MEK-ERK	 axis	 would	 show	 similar	 effects.	 Recently,	 an	 inhibitor	 that	specifically	targets	the	KRASG12C	mutation	has	shown	promising	potency	in	both	lung	and	colorectal	cancers	in	a	phase	I	study	15.	Our	preliminary	results	also	indicate	that	AMG510	enhances	cell	surface	TNFR1	in	a	dose-dependent	manner,	although	not	as	strongly	as	TRA	(data	 not	 shown).	 Importantly,	 the	 combination	 of	 AMG510	 with	 TNFα	 and	 IFNγ	 also	strongly	 induced	cell	death	 in	vitro	(Fig.	4.1A).	The	combination	of	KRASG12C	inhibitors	with	T	cell	therapies	may	be	especially	effective	because	these	inhibitors	specifically	inhibit	MEK-ERK	signaling	in	tumor	cells,	thereby	leaving	T	cell	functionality	intact.	The	next	step	is	to	extend	the	studies	of	KRASG12C	inhibitors	and	investigate	their	therapeutic	potential	in	clinical	settings	in	combination	with	immune	therapy.		 		 Secondly,	the	mechanism	by	which	MEKi	may	enhance	cell	surface	TNFR1	expression	is	not	clear.	Our	results	indicate	that	the	total	protein	expression	of	TNFR1	was	not	impacted	by	 distinct	 MEKi	 (Fig.	 2.4C	 and	 Fig.	 2.6A).	 Consistent	 with	 this,	 we	 did	 not	 detect	 any	substantial	 change	 in	 TNFR1	mRNA	 expression	 after	MEKi	 treatment	 (Fig.	 4.1B).	 These	results	 indicate	 that	 enhancement	 of	 surface	 expression	 is	 not	 due	 to	 increased	de	 novo	synthesis	but	rather	increased	cell	surface	localization	of	TNFR1.	Although	the	mechanism	by	which	MEKi	may	enhance	cell	surface	TNFR1	expression	is	not	clear,	a	previous	study	implicated	 a	 role	 for	 ERK	 sites	 in	 the	 TNFR1	 transmembrane	 domain	 in	 preventing	membrane	 localization	 111.	 To	 investigate	 whether	 MEKi	 enhances	 cell	 surface	 TNFR1	expression	 through	 this	mechanism,	we	mutated	 several	 computationally	 predicted	 ERK	sites	in	TNFR1	and	re-expressed	it	in	TNFR1	knockout	cells.	We	are	currently	determining	the	impact	of	these	changes	on	cell	surface	expression.	If	the	impact	is	significant,	further	
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studies	could	be	done	with	patient	biopsies	in	order	to	understand	whether	those	mutations	occur	in	cancer	patients	and	if	they	are	associated	with	prognosis	and	drug	response.	One	of	our	key	findings	is	that	MEKi-induced	upregulation	of	TNFR1	at	cell	surface	enhances	 TNFα-induced	 NF-κB	 activation	 and	 TNFα	 target	 gene	 expression,	 including	immune	surveillance	genes	such	as	T	cell	chemokines	that	are	jointly	regulated	by	TNFα	and	IFNγ.	The	increase	in	IFNγ	induced	gene	expression	is	likely	to	be	mediated	by	an	increase	in	MEKi-induced	cell	surface	TNFR1	expression,	which	enhances	TNFα	autocrine	signaling	and	synergy	with	IFNγ.	Our	findings	suggest	that	the	upregulation	of	TNFR1	expression	may	provide	 a	 mechanistic	 explanation	 for	 the	 BRAFi/MEKi-mediated	 increase	 in	 tumor	immunogenicity	 seen	 in	melanoma	patients.	 Thus,	 the	 increase	 in	NF-κB	 activity	 evident	after	BRAFi/MEKi	treatment	could	be	mediated	through	an	increased	response	to	TNFα	and	IFNγ	 following	 increased	 TNFR1	 expression.	 Because	 the	 loss	 of	 viable	 cells	 was	 not	increased	by	cytokines	and	MEKi	in	melanoma	cells,	it	is	possible	that	the	combined	immune-stimulatory	effect	of	MEKi	and	cytokines	augments	anti-tumor	activity.	Such	a	differential	impact	of	MEKi	in	melanoma	vs.	lung	tumor	models	requires	further	study.	Previous	studies	have	implicated	the	RAL-TBK1	signaling	arm	of	RAS	in	the	expression	of	pro-inflammatory	cytokines	with	tumor-promoting	functions	(e.g.	IL6)	234.	Based	on	our	findings,	it	will	also	be	interesting	 to	 determine	 whether	 potential	 cross-talk	 between	 TBK1	 and/or	 other	oncogenic	pathways	and	TNFαIFNγ	also	impacts	gene	expression	and	the	cell	death	pathway.	
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